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1. Introduction 
1.1 Megakaryocyte development & maturation in the bone 
marrow and platelet production 
Platelets are small, anucleate, discoid-shaped cell fragments, usually ranging 
from 1 to 3 µm in diameter and the essential cellular mediator of hemostasis. 
They are released into the circulation from the cytoplasm of megakaryocytes 
(MKs), their progenitors, which mature in the bone marrow (BM) and are 
produced from hematopoietic stem cells (HSCs). While MKs are the largest cells 
encountered in the BM by size (50-100 µm), they represent less than 1% of total 
nucleate cells within the BM1. A hallmark event in MK differentiation and 
maturation is endomitosis yielding polyploid MKs which is postulated to be 
necessary for the assembly of the large quantity of granules and organelles 
required in the later platelets. 
For platelet formation, the cytoplasm of the MK is reorganized into long processes, 
designated proplatelets, and finally the multilobulated nucleus of the MK is 
extruded. MKs exhibit roughly 10-20 proplatelets which branch repeatedly and 
therefore allow the generation of estimated 103 platelets per MK2. Proplatelets 
protrude into the blood stream and via intermediate formation of preplatelets the 
mature platelet comes into existence. 
The journey from the early MK to the final platelet can also be divided by time 
length. MK maturation and migration within the BM compartment takes several 
days, whereas the process of proplatelet formation and platelet shedding is 
completed within hours. 
Given the experimental importance of murine models in hemato- and 
megakaryopoiesis it is important to note that platelet production takes 
approximately 5 days in humans, while rodents accomplish platelet production 
within 2-3 days. Platelet lifetime though is longer in humans with 7-10 days, 
whereas it does not surpass 4-5 days in rodents3. 
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1.1.1 From the hematopoietic stem cell to the mature MK 
Like all other hematopoietic cells, MKs develop from multipotent HSCs. MK and 
erythroid lineages are closely related, sharing a common progenitor the 
MK/erythroid-progenitor (ME-P)4. Differentiation from HSCs to MKs is mainly 
driven by thrombopoietin (TPO) and its corresponding MK receptor c-Mpl5. It was 
further shown that differentiation of the ME-P towards the erythroid or 
megakaryocytic lineage downstream of the TPO/Mpl axis is driven by the 
balanced antagonism of the transcription factors FLI1 toward megakaryopoiesis 
and KLF1 toward erythropoiesis6. Recent work, however, suggests that 
megakaryopoiesis can bypass the ME-P stage, when HSCs give rise to MK-
progenitors directly(MK-P)7. In this context, the Bmi1/Runx1 axis is of notable 
interest, as Runx1 is responsible for the epigenetic inactivation of KLF18 and 
Runx1 activation leads to platelet-producing MKs from MK-Ps in vitro9. 
After successful lineage restriction, the MK precursor or promegakaryoblast 
initializes the synthesis of platelet proteins and also increases its ploidy by 
endomitosis. Usually a response to stress in other nucleated cells, polyploidy is 
regularly encountered in MKs with genomic content ranging from 2 to 64N with 
the modal being 16N. It has been speculated that polyploidy facilitates production 
of the huge quantities of mRNA and protein needed in platelets without mitotic 
and cytokinetic stress and helps increase cytoplasm volume more efficiently than 
in mitosis10. Theoretically, it also provides a salvage pathway in case of one-allelic 
mutation of a MK key gene4. 
Although many aspects of endomitosis remain unsolved, it is now believed that 
defects in late cytokinesis are responsible3. For mitosis, formation of a complete 
cleavage furrow is necessary, forming a contractile ring consisting of nonmuscle 
myosin (NM) IIA, NMIIB and F-actin, to effectively separate cells11,12,13. In MKs, 
both the required nonmuscle myosins IIA and IIB are expressed. A recent study 
from Roy et al. showed that basal RhoA/ROCK activity is required for NMIIB 
localization to the cleavage furrow13 and that inhibition of RhoA lead to loss of the 
same, promoting polyploidization. In an earlier study on NMIIB, it was already 
found out that early occurrences of endomitosis (2N – 4N) rely on inactivation of 
the myosin heavy chain (MYH)10 gene-encoded NMIIB in the contractile ring by 
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Runx114, fostering Roy’s results. The authors could also demonstrate that 
RhoA/ROCK signaling affects NMIIA/B localization most likely through increased 
actin turnover and somewhat independently of the classical RhoA/ROCK 
pathway revolving around myosin light chain (MLC) phosphorylation13,15. 
Additionally, RhoA activity-related proteins GEF-H1 and ECT2 were identified to 
play a role in endomitosis and polyploidization in a third study16. GEF-H1 needs 
to be downregulated during the first endomitotic event from 2N to 4N and ECT2 
ever thereafter17, probably signifying a close relationship to RhoA/ROCK and 
NMIIA/B signaling. These results might possibly constitute the molecular basis of 
findings in RhoA-/- mice of increased MK polyploidization, 
macrothrombocytopenia and impaired integrin aIIbb3 outside-in signaling18, as 
deficiency of NMIIA by MYH9 inactivation yielded comparable results. Firstly, 
decreased NMIIA function led to slower MK migration towards the vascular 
niche19. Moreover, MYH9 inactivation was accompanied by defective integrin 
aIIbb3 outside-in signaling and impaired thrombus formation under flow and lastly, 
macrothrombocytopenia as a sign of defective megakaryopoiesis was also 
reported20. 
Maturation of MKs is also connected to their localization in the BM. MKs form in 
the endosteal niche21,22 of the BM and migrate toward the vascular niche23,24,25, 
where they release their platelets2,26. Therefore, MK migration and maturation is 
linked to one another. Attraction of MKs to the vascular niche is mediated by 
chemokines produced by surrounding endothelial and perivascular mesenchymal 
cells27. Of major importance in that journey is the cytokine CXCL12 or previously 
referred to as SDF-1. The corresponding MK receptor CXCR4 is increasingly 
expressed during maturation and administration/stabilization of CXCL12 leads to 
a higher percentage of MKs neighboring BM sinusoids28. By expression of high 
levels of CXCL12 and FGF-4, even TPO/Mpl axis-deficient MKs could be 
recruited to the vascular niche – VCAM-1 and VLA-4-mediated – and shed 
functional platelets29. Adult MKs become unresponsive to CXCL12, however, as 
overexpression of RGS16 attenuates CXCR4 function, hereby reducing retention 
forces and enabling egress of the MK from the BM30,31. It was also shown that 
the Wiskott-Aldrich syndrome protein (WASP) is a crucial player in actin 
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polymerization in hematopoietic cells. Lack of WASP leads to premature 
proplatelet formation as early as in the endosteal niche and the development of 
podosomes which hinder MK migration towards the BM sinus32,33, although this 
migration concept has been contested by recent imaging studies34. 
Another purpose of endomitosis is the generation of the invaginated membrane 
system (IMS), or previously referred to as demarcation membrane system (DMS). 
It has been described as an extensive complex of tubules and cisternae 
permeating the cytoplasm of the MK and primarily functions as a membrane 
reservoir for proplatelet formation3,35,36. Invagination relies on actin-driven 
cytoskeletal remodeling via the WASP/WAVE pathway, downstream of PI-4,5-P2 
signaling37. Membrane cytoskeleton-bridging proteins like CIP4 are also crucial 
in formation of the IMS, as loss of CIP4 results in impaired plasma membrane 
stiffening and reduced proplatelet development, because of aberrant IMS 
formation33,38,39. A recent study was able to show that a ‘pre-IMS’ structure exists 
in immature MKs, thereby proposing a new model for IMS formation which starts 
with focal membrane assembly at one peripheral region of the MK, subsequent 
invagination and finally expansion through lipid transfer from both the golgi 
network and the endoplasmatic reticulum40. 
 
1.1.2 Proplatelet formation and platelet release 
Mature MKs extend long branching protrusions called proplatelets through 
junctions in the lining of blood sinuses of the BM3,41. Only MKs which are able to 
form proplatelets have been shown to successfully produce platelets42,43. The 
process of proplatelet development starts with one membrane region of the MK 
to erode by giving rise to pseudopodial-like structures which begin to elongate, 
branch and taper. Branching is repetitive which helps create the great number of 
proplatelet tips required. In the proplatelet tip, a single microtubule forms a loop 
and reenters the proplatelet shaft. It will later constitute the microtubule coil 
defining the platelet size and its discoid shape41. Studies demonstrated that 
microtubules are the main force driving proplatelet elongation, as drugs effecting 
disrupting microtubule assembly, e.g. colchicine, vincristine or nocodazole 
prevent proplatelet synthesis44. Visualization of microtubule arrangements 
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throughout one MK life cycle showed significant remodeling. Immature MKs 
possess a microtubule arrangement in a starburst pattern with microtubules 
starting from centrosomes. When proplatelet formation begins, cortical 
microtubules are arranged into thick bundles parallel to the plasma membrane 
and later form an array lining the entire length of the proplatelet.  Tapering takes 
place, as microtubule bundles are thick near the proplatelet shaft, whereas only 
5-10 microtubules can be found near the proplatelet tip. Further visualization 
studies using EB3 – binding to the nucleating plus end of microtubules – found 
that proplatelet growth and microtubule assembly rates are not the same, 
indicating a certain amount of independency of one another, and that 
polymerization occurs in both directions, meaning bundles have mixed 
polarity45,46,47. Furthermore, the net plus end oriented motor protein kinesin which 
traffics organelles and cargo, was seen to change direction during its migration, 
supporting the notion of mixed microtubule polarity41. Additionally, when a certain 
degree of proplatelet formation has taken place, blockade of microtubule 
assembly does not attenuate proplatelet growth rates, proposing the parallel-
oriented microtubules bundles possess a sliding mechanism by which they 
mediate elongation. The minus end-oriented motor protein dynein is 
hypothesized to facilitate that sliding, as disruption of its dynactin complex inhibits 
proplatelet elongation which can be recovered in permeabilized MKs by addition 
of excessive amounts of ATP46. Branching of proplatelet processes, with the 
proplatelet usually making a U-turn and the daughter proplatelet emerging from 
the vertex, was shown to be driven by the actin cytoskeleton, as inhibition with 
cytochalasin or latrunculin leads to a failure of proplatelets to bifurcate and 
branch43. 
 
Rho GTPases as general modifiers and effectors of actin-related cytoskeletal 
remodeling were shown to be closely connected to proplatelet formation. RhoA 
for example is hypothesized to regulate thrombopoiesis in late-stage MKs48. 
Knock-out of RhoA produced stiff membranes in the studied MKs and premature 
platelet clearance, suggesting involvement also in proplatelet formation, although 
no observable defect was perceived49. Other researchers addressed RhoA 
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through one of its effector kinases, PKCe. Downregulation of PKCe was 
accompanied by reduced proplatelet length in cultured murine MKs which was 
alleviated by RhoA inhibition50. Substantiating this report is a study which showed 
that constitutively active RhoA also decreases proplatelet length51. Juxtaposition 
of these findings illustrate that RhoA regulation is most likely complex and 
intricately regulated from both a temporal and spatial perspective45.  
A murine double knock-out of Rac1 and Cdc42, two major contributors in 
lamellipodia and filopodia development respectively, showed surprising findings 
and potential redundancy of these two Rho GTPases. Unlike previously believed, 
double deletion of these proteins had minor impact on actin dynamics, whereas 
microtubule formation was severely disrupted, including the marginal platelet 
microtubule coil, yielding morphologically altered proplatelets and larger 
platelets52.  
Research showed that MKs release a heterogeneous cytoplasm mix into the 
circulation, most abundantly proplatelet fractions which form dumbbell-like 
structures3. Recently added as an intermediary stage of platelet production was 
the preplatelet, an immature platelet with dimensions of 3-10 µm in diameter, 
probably either the reason of a still higher mRNA content, ‘young (reticulated) 
platelet’, or as the result of conditions with few and large platelets, i.e. 
macrothrombocytopenia45. Preplatelets were found to interconvert into 
aforementioned dumbbell proplatelets and finally convert to mature platelets 
through microtubule polymerization and subsequent abscission53,54. 
The lung has emerged as a potential organ for the terminal stages of platelet 
maturation, as an early study already found the platelet concentration in 
postpulmonary vessels to be higher than elsewhere in the circulation55 and rat 
models displayed lower platelet counts after lung injury56. Interestingly and 
supporting this thesis is that infused MKs from fetal liver-cell and BM cultures 
predominantly localize to the lung where they release platelets within 2h57. 
 
1.2 The Rho family of small GTPases 
The Rho family of small GTPases was discovered in the wake of the search for 
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Ras-like genes, as Ras had been found to be commonly mutated in human 
carcinomas58 and was identified early on in this effort59,60. With additional 
discoveries made over time, five distinct subfamilies of the Ras-related small 
GTPase superfamily could be established: Ras – constituting its own subfamily 
–, Rho, Rab, Ran and Arf61,62. 
Regarding the Rho (sub)family, three members came into the spotlight, namely 
RhoA, Rac1 and Cdc42, because of their importance for the actin cytoskeleton 
and dynamical rearrangement processes63,64. It could further be shown that RhoA, 
Rac1 and Cdc42 also take part in signaling events concerning cell cycle entry 
and survival, as well as gene expression61,64,65. Not surprisingly, these 3 
GTPases are among the most highly conserved across all eukaryotes, including 
plants and fungi as well66. Research conducted by Hall, Ridley and Nobes yielded 
landmark findings helping understand the roles of the aforementioned proteins67. 
The Rho GTPase Rac was shown to be the major contributor in lamellipodia 
formation68, whereas Rho is necessary in the development of contractile 
actomyosin fibers or so-called stress fibers and focal adhesions69. Cdc42 in turn 
takes part in the formation of filopodia, as was found out in cell experiments70. 
As of recently, also other members within the Rho family – yet again comprising 
8 subgroups with 20 proteins in total71,72 – come into focus. Eight members were 
described as ‘atypical’ owing to their natural GTP-bound state, being the result of 
nucleotide exchange or amino-acid substitutions73. Most commonly, Rho 
GTPases cycle between an active GTP-bound and an inactive GDP-bound form. 
Guanine nucleotide exchange factors (GEFs), guanine nucleotide-dissociation 
inhibitors (GDIs) and GTPase-activating proteins (GAPs) are the main group of 
regulators in this setting74,75,76. Activity of atypical Rho GTPases, however, is 
modulated by protein stability, phosphorylation state and gene expression77. 
Anucleate platelets serve as a prototype of a minimal cell for the study of the actin 
cytoskeleton and microtubule system lacking compensation mechanisms at the 
DNA level78,79. Though there is mounting evidence that platelets possess an 
intact spliceosome, transcriptional factors working in a non-genomic way and 
miRNA indicative of complex post-translational processes which might be 
necessary to maintain the platelet proteome during its life time80,81. 
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1.2.1 RhoA 
RhoA is the most abundantly expressed isoform of the highly homologous Rho 
GTPase proteins RhoA, RhoB and RhoC in human platelets and the sole 
representative in murine platelets16,82,83,84. Studies showed that the clostridium 
botulinum C3 transferase leads to inactivation of Rho GTPases through ADP 
ribosylation which was used to gain insight into their function85,86. RhoA is 
activated by the a-subunits of G-protein coupled receptors (GPCRs) G12/13 and 
Gq in platelets and mediates e.g. platelet shape change, spreading and clot 
retraction18,79,87. 
Due to the fact that platelet shape change occurs also in the absence of Gaq, a 
Ga13-Rho/Rho-kinase-dependent pathway via myosin light chain (MLC) 
phosphorylation was established88. 
Upon activation with thrombin, Ga13 binds to p115RhoGEF which leads to 
nucleotide exchange from GDP to GTP in RhoA, hence activation of the 
GTPase89. The effector protein of RhoA is the Rho-associated protein kinase 
(ROCK) which drives MLC phosphorylation and is ultimately responsible for 
shape change and granule release90,91,92,93. After initial stages of platelet 
activation, the Ga13 subunit associates with integrin aIIbb3 which activates c-Src. 
c-Src then activates p190RhoGAP converting RhoA into a GDP-bound inactive 
state to allow for platelet spreading. By the time clot retraction occurs, platelet 
calcium signaling enhances Calpain protease activity which cleaves the cytosolic 
domain of integrin b3, resulting in promotion of the Ga13-RhoGEF association and 
activation of RhoA another time for clot retraction79,94,95. These processes 
illustrate the complex spatiotemporal regulation of the GTPase. 
Murine models deficient of RhoA exhibited that RhoA is indispensable for platelet 
adhesion under high shear conditions82. Regarding thrombosis and hemostasis, 
RhoA deficiency protects from arterial thrombus formation and ischemic stroke, 
whereas hemostasis is defective, as mouse tail-bleeding assays showed. A 
moderate aggregation defect downstream of both Ga13 and Gaq was seen, too. 
Spreading was not found to be altered on fibrinogen – a substrate of integrin 
 9 
aIIbb318. 
In the light of megakaryopoiesis, RhoA-deficient mice display 
macrothrombocytopenia which is accompanied by an in increase in BM MKs 
stipulating a need for RhoA in later stages of platelet production18,19,51. 
 
1.2.2 Rac1 
First discovered as another substrate of the clostridial C3 enzyme96, Rac has 
emerged as an important player in actin rearrangement processes. The Rac 
family with Rac1, Rac2, Rac3 and RhoG as members, based on homology 
analysis97, was shown to drive lamellipodium and membrane-ruffle formation, as 
well as membrane extension in phagocytosis in nucleated cells98. Several Rac 
GEFs have been shown to mediate Rac activity, including TIAM1, b-PIX and 
DOCK18066,99,100, although the most intensively studied Rac GEFs with regard to 
platelets are the Vav proteins and P-Rex1. Rac then interacts with its 
predominant effector proteins WAVE/Scar, formin protein mDia2 and PAKs which 
in turn activate actin-nucleating proteins, e.g. Arp2/366,101,102, or related 
regulators ,e.g. cortactin and cofilin103,104. Most interestingly, Rho/ROCK 
activation is believed to negatively inhibit lamellipodium formation, as RhoA 
inhibition leads to multiple and larger lamellipodia105, demonstrating the need of 
a balanced activity of pro-migratory proteins and cellular adhesion mediating 
ones66. 
In platelets, only Rac1 is expressed in significant amounts106. Activation of Rac1 
may occur analogous to Cdc42, i.e. by release of  14-3-3z from the GPIb-IX-V 
complex107, when the GPIb receptor is activated by vWF87. Signaling through Gi 
coupled platelet receptors such as P2Y1 alone cannot activate Rac1 sufficiently, 
whereas their signaling is required for full activation108,109. In case platelet 
activation occurs through receptor GPVI or integrin aIIbb3, Rac1 activation is 
mediated through the Src family kinase, SFK106,110,111 and Rac1 then activates 
PLCg2. Platelet activation through Gaq coupled GPCRs occurs via agonists ADP, 
thrombin and TxA2 and has been shown to activate PLCb which also activates 
Rac1 112. As PLCs regulate calcium release through IP3 and DAG, it becomes 
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visible that Rac1 modulates calcium-mediated signaling at different stages, 
finding itself up- and downstream of PLCs. Exemplary of this observation is that 
while PI3K activation is needed for Rac1 to become fully active, it is also a 
reported activator of PI3K at the same time113. 
In platelet function, Rac1 is required for lamellipodia formation which was learned 
from spreading experiments on fibrinogen-, vWF-, laminin- and collagen-coated 
surfaces106,114. Aggregation and platelet activation exhibited defects in the setting 
of collagen and CRP activation, too, strengthening the importance of Rac1 in the 
GPVI-ITAM-Src pathway of platelet activation115. Rac1-deficient mice also lack 
stable thrombus formation106,115. It is not clear, however, if this is due to defective 
lamellipodia formation or because of a lack of platelet activation and consecutive 
scarcity of secondary messengers with the latter explanation being substantiated 
by two works so far115,116. This supports a role for Rac1 in platelet granule release 
which is backed by studies on nucleated cells which exhibit secretion and 
exocytosis deficits, when Rac1 is absent117,118. 
Rac1-deficient mice do not exhibit thrombocytopenia, indicating potential 
dispensability of the GTPase in light of megakaryopoiesis and platelet 
biogenesis115. 
 
1.2.3 Cdc42 
The third extensively studied Rho GTPase, Cdc42 was first described by 
researchers studying cell polarity in yeast119,120. While several small Rho 
GTPases, including RhoD, RhoF, RhoQ and RhoU have been characterized with 
regard to filopodia formation58,72,121,122, Cdc42 probably remains the most 
important one in nucleated cells70,123,124, as well as platelets125,126. Development 
of filopodia can also occur in settings void of Cdc42 which is then attributed to 
the small GTPase Rif or RhoF127,128,129. 
It might be possible that two distinct entities of filopodia exist101, because cultured 
cells expressing Rif display long, thin and flexible filopodia58,130, whereas those 
of Cdc42 are shorter and thicker, at the same time being restricted to the cell 
periphery131. 
Additional roles for Cdc42 have been outlined regarding secretion and 
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exocytosis132,133, too. Cdc42 can be activated through soluble agonists, e.g. 
TRAP and ADP, by activation of PARs which leads to relocalization of the 
GTPase from the membrane to the cytosol134,135. Another activation pathway is 
through 14-3-3z which is released from the GPIb-IX-V complex upon exposure to 
vWF107. 
No specific GEFs for Cdc42 have been reported so far79. Vav proteins, although 
preferentially working through Rac1, also mediate Cdc42 activity79. Noteworthy 
effector proteins of the small GTPase include WASP and N-WASP which induce 
branching of actin via Arp2/3136,137,138, however, this pathway was later proven 
redundant regarding overall filopodia formation ability139. Further well-established 
links between Cdc42 and actin rearrangement processes and dynamics are 
through effector proteins mDia2 and PAKs140,141. PAK in turn activates LIMK 
which phosphorylates cofilin and renders the protein inactive72. Contradicting this 
activation pattern are findings that Cdc42-deficient neurons also show increased 
cofilin phosphorylation which adds to the complexity of the Cdc42/cofilin 
relationship142,143. Further studies established additional effectors, e.g. IRSp53 to 
convey filopodia formation144. By now more than 70 Rho GAPs have been 
discovered – usually inactivating RhoGTPases – but few have been extensively 
characterized unfortunately76. Regarding Cdc42 and Rac1, IQGAP2, OPHN1 and 
Nadrin have been shown to regulate GTPase activity145,146,147,148. 
Study of Cdc42 in the light of platelet function generated mixed results, maybe 
due to differences in methodical approaches125,126,149. Generation of filopodia was 
diminished downstream of GPIb, but neither GPVI nor integrin aIIbb3. Granule 
release was also upregulated in this study149. Another group found filopodia 
formation also to be impaired on fibrinogen and CRP, at the same time reporting 
reduced secretion in Cdc42-deficient platelets125. Due to these results, further 
studies seem warranted to clarify Cdc42 function in platelet activation. 
With regard to MK maturation and HSC differentiation, Cdc42 is not dispensable, 
as deletion leads to defective differentiation and homing/lodging of MKs150,151. 
Cdc42 deficiency is even accompanied with a reduction of Rac1 activity127,152, 
whereas upregulation of Cdc42 leads to faster migration in HSC/progenitor 
cells153. Apparently, Cdc42 positively influences Rac activity and therefore 
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lamellipodia formation72. Concerning MK development, early stages of MK 
development do not seem to rely on both Cdc42 and Rac1, as ploidy does not 
deviate from wild-type (wt) MKs, indicating endomitosis is not impaired52. 
However, at later stages when the focus shifts towards the ability of the MK to 
produce platelets, it was reported that proplatelet formation is diminished in 
Cdc42-deficient mice, as well as structural integrity of MKs is reduced52. This 
observation might explain in part, the reported macrothrombocytopenia found in 
an earlier study149. 
 
1.2.4 G protein coupled receptors G12 and G13 
The G12 and G13 receptor couple to heterotrimeric G proteins on their cytosolic 
end154. Both receptors are interaction partners of protease-activated receptors 
(PARs) upon stimulation. G12-deficient mice are phenotypically normal. In case 
of G13, its effect is mediated through the a-subunit of the G protein which 
regulates signaling in the RhoA/ROCK pathway by binding to RhoGEF and 
subsequent activation of the GTPase RhoA. Lack of G13, but not G12 is 
accompanied by defective shape change and aggregation at low and 
intermediate concentrations of PAR4 receptor agonists like thrombin, U46 or 
TxA2. This effect can be overcome by use of high agonist concentrations yielding 
unaffected platelet shape change. Additionally, in double knock-out G12/13-/- mice, 
there is no aggravation of the phenotype observed in G13-deficient mice. At high 
levels, TxA2 and thrombin couple to Gq receptors which can also activate the 
RhoA/ROCK axis. On the other hand, elaborate platelet functions such as 
degranulation or aggregation requiring a higher degree of platelet activation 
cannot be mediated by activation of the G13 axis alone, as Gq-deficient platelets 
are impaired in these regards79,154,155. 
Signaling through both pathways ultimately leads to a net increase of myosin light 
chain (MLC) phosphorylation, yet through different mechanisms. G13 signaling 
works through the RhoA/ROCK axis and results in reduced MLC phosphatase 
activity by phosphorylation. Gq signaling on the other hand elevates intracellular 
Ca2+ levels fostering MLC kinase and hence MLC phosphorylation155. 
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1.2.5 RhoF 
A more recent addition to the small GTPase family was RhoF or Rif101. It is most 
closely related to RhoD within the family, but only shares low overall homology156. 
It is not ubiquitously expressed, unlike RhoA, Rac1 and Cdc42, but can be found 
in MKs and platelets84,97,157 and has been shown to also drive filopodia 
formation58,130. High expression levels have also been found in malignant B-cell 
lymphoma and were hypothesized to promote malignant transformation158. 
To date, no specific GEFs, GAPs or GDIs for RhoF have been established, when 
compared to a list of the most prevalent aforementioned proteins, compiled by 
Goggs et al101. The same group is in the process of identifying potential 
interaction partners, but their observations have not been published yet. 
Regarding potential effector proteins of RhoF, observations confirmed interaction 
with mDia1, mDia2 and mDia3, proposing a function similar to those of RhoA 
(mDia1) and Rac1 and Cdc42 (mDia2, mDia3)159. 
Filopodia development triggered by RhoF lead to longer and thinner protrusions, 
than those produced by Cdc42, as mentioned before131. This might be due to the 
influence of mDia1 which is not known to activate Cdc42 and therefore might 
explain the discrepancy between the observed phenotypes128,129. Supporting its 
link to mDia1 activity is stress fibre formation – usually the domain of RhoA – in 
HeLa cells160.  
Generation of RhoF-deficient mice was helpful to assess potential effects of a 
knock-out of the GTPase in platelet function and consequently hemostasis and 
thrombosis161. Hematologic indices, activation patterns, integrin signaling and, 
most importantly, adhesion assays were unaltered though, in line with the 
redundant activation patterns of the so far established interaction partners, i.e. 
mDia proteins. It seems likely more effector pathways for RhoF exist, as mDia1-
deficient mice were comparable to wt, especially regarding filopodia formation162, 
indicating the differences in RhoF- and Cdc42-induced filopodia might be 
explained by other pathways than mDia1. 
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1.4 Platelet activation and signaling in thrombus formation 
Platelets are the cellular mediators of hemostasis and essential in forming a 
primary plug at sites of vascular injury to prevent further blood loss of the 
organism163. Dysregulation of this intricate balance of pro- and anti-coagulant 
factors including platelets may result in arterial or venous thrombosis and can 
lead to cardiovascular diseases, e.g. myocardial infarction and stroke. 
Upon contact with components of the extracellular matrix (ECM), platelet 
receptors GPIb-IX-V and GPVI are activated, leading to primary cellular 
responses which are upheld by subsequent signaling of GPCRs and autocrine 
self-activation by platelet-released pro-coagulatory molecules. These events lead 
to transformation of the fragile initial platelet plug to a firmly-adhered blood clot, 
allowing appropriate thrombus growth87. 
 
1.4.1 Overview of involved platelet receptors and signaling pathways 
After binding of circulating von Willebrand factor (vWF) to the exposed ECM, 
platelet deceleration and tethering takes place by binding of platelet glycoprotein 
(GP) receptor GPIb-IX-V to the vWF multimers. These rolling platelets are able 
to interact with collagen via platelet receptor GPVI, initiating shape change from 
a discoid to a spherical shape and cellular activation. One part of the following 
intracellular events comprises the exocytosis of preformed cytoplasmic vesicles, 
so-called a- and dense granules which serve as potentiators of the platelet 
coagulant response and lead to the generation of thromboxane A2 (TxA2). With 
respect to a-granules, pro-coagulatory molecules vWF and fibrinogen are 
released which recruit additional platelets to the injured site, whereas in dense 
granules, e.g. ADP, ATP, TxA2 and serotonin can be found which are termed 
second wave mediators because of their autocrine signaling effects which further 
sustain platelet activation. These signaling pathways converge in transformation 
of platelet integrins from an inactive low-affinity to a functional high-affinity state 
securing firm adhesion of platelets to the ECM and platelet-platelet binding for a 
stable thrombus87,90,155,163, see also Fig. 1. 
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Fig. 1. Platelet activation model. Damage to the endothelial lining results in exposure of 
subendothelial ECM proteins with binding of vWF and exposure of collagen. Platelet tethering is 
then mediated by platelet vWF receptor GPIb which in turn allows binding of the platelet GPVI 
receptor to collagen, effectuating platelet activation, exocytosis of stored granule content, 
thromboxane A2 generation and integrin transformation. Likewise exposed tissue factor initiates 
the plasmatic coagulation cascade resulting in thrombin generation, additionally serving as a 
strong platelet activator. Finally, integrins a2b1 and aIIbb3 secure the platelet plug at the injured 
site and allow for thrombus growth by interconnecting platelets. Taken from Stegner et al.87.  
 
Two major activation pathways in platelets exist: one involves signaling through 
platelet GPCRs with ADP, thrombin and TxA2 as agonists, while the other is 
based on tyrosine phosphorylation of respective receptors GPVI or C-type lectin 
receptor 2 (Clec-2) via the associated immunoreceptor tyrosine activation motif 
(ITAM) or (hem)ITAM87. 
Soluble agonists activate either Gq proteins and hence PLCb, yielding inositol-
1.4.5-triphosphate (IP3) and diacylglycerol (DAG)112 which helps elevate 
intracellular calcium levels required for full platelet activation and granule release 
or G12/13 proteins which signal through the RhoA/ROCK axis, leading to platelet 
shape change89. 
 
1.4.2 The role of platelet receptor GPIb-IX-V in hemostasis and thrombosis 
Platelets rapidly decelerate upon exposure and binding of vWF to their GPIb-IX-
V receptor complex, enabling a first contact with the ECM which is mandatory for 
any further platelet activation to occur164,165.  
Recent models suggest that additionally, a high shear force-driven GPIb 
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activation pathway, e.g. in stenosed arteries exists166,167, but not contradicting the 
GPIb-mediated adhesion model. 
GPIb signaling in general leads to downstream activation of 14-3-3z which 
induces mainly PI3K- and Src-related signaling and PLCg163 activity, leading to 
mild direct activation of the main platelet integrin aIIbb387, see also Fig. 2. 
However, amplification pathways through TxA2, ADP and PLD are further 
initiated163. Most interestingly, mice deficient of PLD isoform D1 displayed an 
activation defect on vWF at high shear rates, but not in tail bleeding assays, 
making it an interesting antithrombotic target 168. Furthermore, mouse models 
deficient of either the GPIba or GPIbb subunit reproduced a congenital bleeding 
disorder seen in humans named Bernard-Soulier syndrome, suggesting an 
essential role for the receptor in thrombus formation169,170. At the same time, 
blockade of GPIba has been proposed as an antithrombotic target, as skin 
bleeding time in baboons was not significantly prolonged171 and mice were 
profoundly protected from secondary infarct growth in a stroke model172,173. 
 
1.4.3 The role of platelet receptor GPVI in hemostasis and thrombosis 
The collagen receptor GPVI contains an ITAM domain, itself bearing Fc receptor 
(FcR)g-chain dimers and is exclusive to MKs and platelets174. Once activated, Src 
family kinases (SFK) mediate further phosphorylation with the help of adaptor 
proteins linker of activated T-cells (LAT) and SLP-76, leading to calcium elevation, 
integrin activation and granule release via PLCg2 and PI3K pathways174,175, see 
also Fig. 2. GPVI is responsible to mediate firm adhesion to ECM components, 
but requires the help of integrins aIIbb3 and a2b1 which undergo a 
conformational change upon GPVI-induced signaling176, resulting in stable and 
shear-independent adhesion. Studies using GPVI/FcRg-chain-depleted mice 
showed marked protection from arterial thrombosis in ischemic stroke 
models172,177,178. Moreover, a knock-out model of integrin a2b1 alone did not find 
observable defects in hemostasis, whereas combined integrin a2b1 and GPVI 
deficiency resulted in drastically impaired hemostatic function179,180. 
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Fig. 2. Overview of platelet receptors and major signaling pathways. Soluble agonists and 
ECM components couple to a multitude of platelet receptors which are linked on their cytoplasmic 
ends to either G-proteins or ITAM or (hem)ITAM domains. Downstream, phospholipase signaling 
and small molecules lead to increases in intracellular calcium levels for farther platelet activation 
or directly influence the platelet cytoskeleton to induce shape change, aggregation, secretion and 
integrin activation. Phospholipase (PL) Cγ2 and b. TF tissue factor, TxA2 thromboxane A2, TP 
TxA2 receptor, PAR protease-activated receptor, RhoGEF Rho-specific guanine nucleotide 
exchange factor, PI3K phosphoinositide-3- kinase, AC adenylyl cyclase, PIP2 
phosphatidylinositol-4,5- bisphosphate, PIP3 phosphatidylinositol-3,4,5- trisphosphate, IP3 
inositol-1,4,5-trisphosphate, DAG diacylglycerol. Taken from Stegner et al.87. 
 
1.4.4 Platelet receptor Clec-2 and GPCRs in hemostasis and thrombosis 
Similarly functioning receptor Clec-2 was a more recent addition to the canon of 
platelet receptors. Originally discovered as a receptor for the snake venom 
rhodocytin181, the endogenous ligand remains unknown, although shown to be 
present on activated platelets182. Observations of both antibody-treated and Clec-
2 knock-out mice showed reduced thrombus formation in arterial and venous 
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models, indicative of its involvement and importance in hemostatic processes. So 
far, it is known that regulation and inhibition of Clec-2 signaling is subject to 
immunoreceptor tyrosine-based inhibition motif (ITIM) bearing receptors such as 
PECAM-1 or G6b-B, but their role in hemostasis and thrombosis remains poorly 
understood up to now87,183,184. 
 
GPCR-mediated signaling is the other main pillar of platelet activation. Most 
notable receptors in this regard are P2Y1 and P2Y12 which are activated by ADP 
and signal through Gq and Gi2/3 respectively185. Main effect of their signaling is 
intracellular calcium release which is in turn required for shape change and 
aggregation 186. P2Y1 knock-out leads to ubiquitous response defects upon 
activation with all major platelet agonists and to increased bleeding times in 
vivo187. Another receptor in this context is P2X1 which is an ATP-gated cation 
channel, guiding mainly calcium into the platelet, thereby also facilitating calcium-
dependent shape change. Deficiency of P2X1 results in partial protection against 
thromboembolism, whereas overexpression promotes thromboembolism188,189. 
TxA2 is a so-called second wave mediator, being released from dense granules190 
and activates thromboxane-prostanoid (TP) receptors TPa and TPb87. Both 
receptors are coupled to G12/13 and Gq, but signaling is considerably weaker than 
through thrombin receptors which share the same effector pathway155. This is 
also illustrated by the limited activation potential of the TxA2 analogue U46619 
(U46) itself and mainly enhances effects of other agonists163. Patients with 
mutated TP receptors exhibit a mild bleeding phenotype32 which is mirrored in 
mouse TP receptor knock-out studies191. 
The most potent soluble platelet activator, however, is thrombin, a serine 
protease which is the final end point of both the plasmatic extrinsic and intrinsic 
coagulation pathway and next to platelet activation also converts fibrinogen into 
fibrin87. Isoform expression of thrombin receptors varies among mammals with 
humans expressing protease-activated receptor (PAR)1 and PAR4, whereas 
mice express PAR3 and PAR4. In both species, studies revealed that PAR1/3 
function as a co-activator of PAR4 which is usually activated only by high 
concentrations of thrombin192,193,194,195. Deficiency of PAR4 abolished thrombin 
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signaling in platelets and protects mice from thrombosis, at the cost of increased 
bleeding propensity196,197. 
 
1.4.5 Downstream signaling, autocrine self-activation and final stages of 
activation  
Activation pathways in platelets are numerous and comprise a vast variety of 
kinases, nucleotides and effector proteins. Among them, PI3K, cAMP, cGMP, 
MAPK and PLA2 are comprehensively described in the literature198,199,200. 
Ultimately, platelet activation and signaling leads to an increase of intracellular 
calcium which is the prerequisite to many subsequent events87. As this work will 
later focus on attachment of platelets and spreading on immobilized surfaces, 
platelet glycoprotein and integrin signaling will be discussed in more detail. 
Four isoforms of type I phosphoinositide 3-kinases (PI3K) exist, i.e. p110a,  
p110b, p110d and p110g198. p110b and p110g appear as promising antithrombotic 
targets, as their deficiency is not paired with a bleeding propensity201,202. Deletion 
of the catalytic p85 subunit leads to a combined reduction of expression levels of 
p110a, p110b and p110g at the same time which makes it a useful tool to 
investigate the overall function of PI3Ks198. Despite being responsive to basically 
all common platelet activators, p85-deficient platelets are defective in platelet 
aggregation, spreading and in response to collagen, establishing PI3Ks as 
effector molecules in GPVI signaling. Furthermore p110d deficiency studies 
showed impaired lamellipodia formation on CRP and collagen suggesting their 
involvement in cytoskeleton processes as well203,204. 
Cyclic nucleotides (cAMP, cGMP) on the other hand have been shown to 
negatively regulate platelet activation. Platelet antagonists like PGE1 or PGI2 
couple to stimulatory G proteins on the platelet membrane and sustain adenylyl 
and guanylyl cyclase function, thereby increasing available cAMP and cGMP 
levels leading to stabilization of the actin cytoskeleton and inhibition of the 
fibrinogen receptor activation. cAMP and cGMP effectors include mainly their 
respective protein kinases cAMP-PK and cGMP-PK200. Vasodilator-activated 
phosphoprotein (VASP) finds itself downstream of both cAMP-PK and cGMP-PK. 
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Its phosphorylation goes in hand with diminished actin polymerization and 
inhibition of the fibrinogen receptor aIIbb3205,206. Phosphorylation of ABP, a 
downstream protein of cGMP has also been linked to impaired fibrinogen binding 
in a ADP-induced setting of activation207 and increased cytoskeletal stability208. 
Additionally, phosphorylation of GPIb of the GPIb-IX-V complex by PGE1 was 
accompanied with reduced collagen-mediated actin polymerization209. Together 
these studies illustrate how rises in cAMP and cGMP levels negatively influence 
platelet adherence or spreading upon contact with components of the ECM like 
fibrinogen or vWF. 
Also at the level of transcription factors, signaling through collagen and vWF 
receptors GPVI and GPIb can be impaired as deficiency of GATA1 shows32,210. 
 
Integrin adhesion receptors or integrins mediate shear-resistant and sustained 
adhesion to the ECM and various isoforms are expressed in platelets. Integrins 
are heterodimers composed of a transmembranous a- and b-chain respectively. 
Three b1-isoforms can be found in platelets with a5b1 constituting a fibronectin 
receptor, a6b1 a laminin receptor and a2b1 a collagen receptor87. b1-isoforms 
are believed to play only a supportive role in platelet adhesion, as knock-out 
models of integrin a2b1 failed to exhibit major hemostatic deficiencies179,211,212. 
This is most likely due to the fact that the most abundant platelet integrin aIIbb3 
is compensating for the loss, enabling the platelet to attach to the ECM also under 
high shear stress212. The other b3-isoform is integrin aVb3, binding partner of 
fibronectin, osteopontin and vitronectin. Low expression levels, however, 
precluded it from extensive scientific interest which is why its function is not well 
characterized87. On the other hand, aIIbb3 has always been in the focus of 
platelet research. Lack of integrin aIIbb3 in humans leads to Glanzmann 
thrombasthenia, exhibiting severe activation defects upon stimulation with major 
agonists and resulting in mucocutaneous bleeding213. In mouse models, similar 
results can be gained by deletion of the aIIb- or b3-subunit with absence of 
platelet aggregation, lack of thrombus formation and even spontaneous 
bleeding87. Integrin aIIbb3 has several ligands, the most important being 
fibrinogen by bridging platelets to one another in the developing clot. Its protease-
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cleaved form fibrin secures the clot at the site of the vascular injury. Fibrinogen 
deficiency analogously leads to spontaneous bleeding and a failure of platelets 
to aggregate214. Certain mutations of integrin aIIbb3 involving Arg995 and 
Asp723 of the respective subunits were shown to correlate with an increased 
activation state of the integrin resulting in down-regulation of RhoA and impaired 
megakaryopoiesis215. 
The multimer vWF is an additional ligand of integrin aIIbb3 and required for 
platelet bridges at high shear rates216. Another interaction partner is CD40 ligand 
whose role has been addressed in knock-out studies. Lack of CD40 ligand is 
accompanied with impaired integrin aIIbb3 outside-in signaling in arterial flow and 
therefore high shear settings. Once integration of the thrombus is mediated by 
integrin aIIbb3, other proteins, including ephrin kinases, Gas6 and ESAM take 
over and affect thrombus stability217. 
Upon activation, integrins undergo conformational changes from a low- to a high-
affinity state which coined the term inside-out signaling in platelet research. This 
remodeling is necessary for integrins to bind to their ligands and mediate their 
effects. As soon as ligands have bound, integrins activate cellular response 
pathways which was in turn named outside-in signaling218. 
Important interaction partners of integrins comprise talin1 and kindlin3. Actin-
binding protein talin1 associates with Rap1-interacting adaptor molecule 
(RIAM)219 to mediate its effect on integrin aIIbb3. Studies on knock-out mice 
lacking talin1 found abrogation of inside-out integrin activation, spreading defects 
on fibrinogen – substantiating also impaired outside-in signaling – and total 
insufficiency of primary hemostasis in vivo220,221. Talin1 relies on phospholipid 
PIP2222 for integrin binding which might be the link to how PLD1 modulates 
integrin activity, as it enhances PIP2 concentrations through respective kinases. 
Kindlin3, sometimes termed Fermt3, also influences integrin b-chain activity, as 
deficiency of the integrin adaptor molecule mimics the above described 
phenotype of talin1-deficient mice and talin1 cannot operate alone in integrin 
activation, either, indicative of the existence of other regulators like kindlin3223. 
Recently, mutations of kindlin3 were first observed in humans224,225 with patients 
suffering from recurrent clinical bleeding, hence exhibiting features already seen 
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in kindlin3-deficient mice226. 
 
1.5 Aim of the study 
With the establishment of MK and platelet-specific knock-out mouse models for 
the small Rho GTPases RhoA, Rac1 and Cdc42 insight into their function in 
platelet biology could be gained. RhoA and Cdc42 deficiency were shown to be 
accompanied by defects and alterations in granule secretion, as well as more and 
less pronounced macrothrombocytopenia respectively. With regard to Cdc42 
deficiency, impaired filopodia formation downstream of GPIb signaling was 
observed, too18,149. 
This study wants to address the functions of predominantly RhoA and Cdc42 in 
megakaryopoiesis and involved signaling pathways in formation, maturation and 
migration of MKs in the BM to supplement our understanding of these GTPases 
in the field of platelet and MK biology. 
Therefore, appropriate knock-outs and double knock-outs of RhoA and Cdc42 
were generated and studied with respect to MK numbers in the BM, as well as 
their localization. In a second step, pathways potentially involved in migration and 
MK localization in the bone marrow of RhoA knock-out mice were examined by 
antibody treatment of mice. 
A smaller part of this work is directed at a more recent addition to the small 
GTPase family, namely RhoF and its role in filopodia formation. RhoF, next to 
Cdc42 has been hypothesized to play a role in filopodia development and for this 
reason a MK and platelet-specific knock-out mouse was generated in order to 
study the effects of RhoF loss in the setting of platelet activation, degranulation 
and most importantly spreading on immobilized surfaces downstream of GPIb 
and fibrinogen signaling129,160,161. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
acetic acid Roth (Karlsruhe, Germany) 
ADP Sigma (Schnelldorf, Germany) 
agarose Roth (Karlsruhe, Germany) 
agarose, low melting Euromedex (Souffelweyersheim, 
France) 
ammonium peroxodisulfate (APS) Roth (Karlsruhe, Germany) 
apyrase (grade III)    Sigma (Schnelldorf, Germany) 
Aquatex Merck (Darmstadt, Germany) 
bovine serum albumin (BSA)          AppliChem (Darmstadt, Germany) 
calcium chloride Roth (Karlsruhe, Germany) 
Complete mini protease inhibitors 
(+EDTA)                           
Roche Diagnostics (Mannheim, 
Germany) 
convulxin Alexis Biochemicals (San Diego, USA) 
dNTP mix                                                                                                 Fermentas (St. Leon-Rot, Germany) 
EDTA AppliChem (Darmstadt, Germany) 
eosin   Roth (Karlsruhe, Germany) 
epinephrine Sigma (Schnelldorf, Germany) 
ethanol                     Roth (Karlsruhe, Germany) 
Eukitt mounting medium                         Sigma (Schnelldorf, Germany) 
fluorescein-isothiocyanate (FITC)      Molecular Probes (Oregon, USA) 
Forene® (isoflurane) Abott (Wiesbaden, Germany) 
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Fura-2 acetoxymethyl ester (AM) Molecular Probes (Oregon, USA) 
gelatine capsules Agar scientific (Stansted, England)  
GeneRuler 1kb DNA Ladder                 Fermentas (St. Leon-Rot, Germany) 
glucose Roth (Karlsruhe, Germany) 
hematoxylin                                  Sigma (Schnelldorf, Germany) 
HEPES Roth (Karlsruhe, Germany) 
high molecular weight heparin        Sigma (Schnelldorf, Germany) 
human fibrinogen Sigma (Schnelldorf, Germany) 
human vWF CSL Behring (Hattersheim, Germany) 
igepal CA-630           Sigma (Schnelldorf, Germany) 
integrilin                                             GlaxoSmithKline (Germany) 
isopropanol            Roth (Karlsruhe, Germany) 
6x Loading Dye Solution         Fermentas (St. Leon-Rot, Germany) 
magnesium chloride Roth (Karlsruhe, Germany) 
paraformaldehyde Roth (Karlsruhe, Germany) 
phenol/chloroform/isoamylalcohol AppliChem (Darmstadt, Germany) 
potassium acetate                                                  Roth (Karlsruhe, Germany) 
prostacyclin Calbiochem (Bad Soden, Germany) 
R-phycoerythrin (PE) EUROPA (Cambridge, UK) 
Rotiphorese Gel 30 (PAA) Roth (Karlsruhe, Germany) 
sodium azide Roth (Karlsruhe, Germany) 
sodium chloride           AppliChem (Darmstadt, Germany) 
sodium cacodylate Roth (Karlsruhe, Germany) 
tannic acid Merck (Darmstadt, Germany) 
Taq polymerase                Fermentas (St. Leon-Rot, Germany) 
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Taq polymerase buffer (10x) Fermentas (St. Leon-Rot, Germany) 
TEMED             Roth (Karlsruhe, Germany) 
3,3,5,5-tetramethylbenzidine (TMB) EUROPA (Cambridge, UK) 
thrombin Roche Diagnostics (Mannheim, 
Germany) 
U-46619              Alexis Biochemicals (San Diego, USA) 
 
Botrocetin was procured from Francoi Lanza (EFS Alsace, Strasbourg, France). 
S.P. Watson (University of Birmingham, UK) generously provided collagen-
related peptide (CRP).  Rhodocytin was kindly donated by Johannes Eble 
(University Hospital Frankfurt, Germany). All other non-listed chemicals were 
obtained from either AppliChem (Darmstadt, Germany), Sigma (Schnelldorf, 
Germany) or Roth (Karlsruhe, Germany). 
 
2.1.2 Kits 
PCR 
PCR Extender System 5 PRIME (Hamburg, Germany) 
GeneAmp XL PCR Kit Applied Biosystems (New 
Jersey, US) 
Triple Master PCR System Eppendorf (Hamburg, 
Germany 
 
Immunohistochemistry 
Peroxidase Labeling Kit Roche (Mannheim, Germany)  
 
 
2.1.3 Antibodies 
Polyclonal and monoclonal antibodies that were used in this thesis can be found 
in the following subsections. 
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2.1.3.1 Purchased primary and secondary antibodies 
rabbit anti-human vWF antibody DAKO (Hamburg, Germany) 
anti-integrin b1chain (CD29) 9EG7 BD Pharmingen 
rat anti-mouse GPIba antibody Emfret Analytics (Wuerzburg, 
Germany) 
rat anti-mouse IgG-HRP DAKO (Hamburg, Germany) 
 
2.1.3.2 In-lab generated and modified monoclonal antibodies 
antibody name clone isotype antigen description 
JAQ1 98A3 IgG2a GPVI 227 
DOM1 89F12 IgG2a GPV 228 
DOM2 89H11 IgG1 GPV 228 
JON/A    4H5 IgG2b GPIIb/IIIa 229 
LEN1 12C6    IgG2b α2 integrin 230 
WUG1.9 5C8 IgG1 P-Selectin unpublished 
ULF1 97H1 IgG2a CD9 unpublished 
p0p4 15E2 IgG2b GPIba 228 
p0p6 56F8 IgG2b GPIX 168 
JON6 14A3 IgG2b α2bb3 
integrin 
unpublished 
INU1  11E9 IgG1 Clec-2 182 
p0p5 13G12 IgG1 GPIba 228 
p0p3 7A9 IgG2a GPIba 231 
 
2.1.4 Buffers and solutions 
Buffers were prepared and diluted according to protocol using aqua ad iniectabilia 
(DeltaSelect Pfullingen, Germany) or deionized water obtained from a MilliQ 
Water Purification System (Millipore, Schwalbach, Germany). pH adjustment was 
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performed with HCl or NaOH. 
 
Acid-citrate-dextrose (ACD) buffer, pH 4.5 
citric acid anhydrous 65 mM 
glucose anhydrous 110 mM 
trisodium citrate dehydrate 85 mM 
 
Blocking solution for immunohistochemistry 
BSA 3% 
rat serum 0,3% 
TBS-T  
 
Decalcification buffer 
EDTA 10% 
PBS  
 
 FACS buffer 
BSA 0,1% 
NaN3 0,02% 
PBS  
 
Lysis buffer for DNA sampling from mouse tissue 
EDTA (0,5 M) 5 mM 
NaCl 200 mM 
SDS 0,2% 
TRIS base 100 mM 
add Proteinase K (20 mg/ml) 100 µg/ml 
 
Phosphate buffered saline (PBS), pH 7.14 
KCl 2,7 mM 
KH2PO4 1,5 mM 
NaCl 137 mM 
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Na2HPO4x2H2O 8 mM 
 
Tris-buffered saline (TBS), pH 7.3 
NaCl 137 mM 
TRIS/HCl 20 mM 
 
TE buffer, pH 8 
EDTA 1 mM 
TRIS base 10 mM 
 
Tyrode’s buffer, pH 7.3 
BSA 0,35% 
CaCl2 1 mM 
glucose 0,1% 
HEPES 5 mM 
KCl 2.7 mM 
MgCl2 1 mM 
NaCl 137 mM 
NaHCO3 12 mM 
NaH2PO4 0.34 mM 
 
2.2 Methods 
2.2.1 Creation of ko and dko mouse strains 
All knock-out (ko) and double-knock-out (dko) mouse strains studied in this thesis, 
i.e. RhoA, RhoA/Cdc42, G12/13 and RhoF were created using a loxP/PF-4 Cre 
gene deletion approach. Hereby, the gene in question is introduced to flanking 
loxP sites and mice were accordingly labeled, e.g. RhoFfl/fl 232. Floxed (fl) mice 
were crossed with mice containing the MK- and platelet specific promoter platelet 
factor 4 (PF4) Cre recombinase. This Cre recombinase is located downstream of 
PF-4 which gets activated during MK maturation and hence provides a lineage 
specific knock-out233 with combined labeling being, e.g. RhoAfl/fl,PF-4Cre +/-. The Cre 
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recombinase excises the loxP flanked regions, leading to loss of the gene product 
and resulting in the respective knock-out. 
RhoA and Cdc42 floxed mice were generously provided by Cord Brakebusch 
(Copenhagen, Denmark). Mice containing the PF-4 Cre recombinase were a gift 
from Radek Skoda (Basel, Switzerland). RhoF floxed mice were generated by 
ordering targeted ES cells from KOMP. 
Mice were maintained on a SV/129/C57/Bl-6 background. 8- to 13-week-old mice 
of mixed gender were used for all experiments, if not stated otherwise. 
 
2.2.2 Genotyping of mice 
2.2.2.1 Mouse DNA sample isolation 
For DNA sampling, a 5mm2 area of ear tissue was obtained. Dissolved in 500 μL 
DNA lysis buffer, samples were incubated overnight at 56°C and shaken at 900 
rpm. After addition and mixing of 500 μL phenol/chloroform, samples were 
centrifuged at 14000 rpm for 10 min at room temperature (RT). The upper phase 
was transferred into a new tube containing isopropanol (1:1 vol). Samples were 
subsequently centrifuged at 14000 rpm for 10 min at 4°C. The resulting DNA 
pellet was then resuspended in 70% ethanol and centrifuged as before. This 
washing step was repeated and the resulting DNA pellet was ultimately 
resuspended in 100 μl TE buffer. Genotyping by PCR was performed using 2 μl 
DNA solution. Following the PCR reaction, separation on agarose gels for ko/wt 
analysis was conducted. Sampling was kindly performed by Sebastian Dütting, 
Deya Cherpokova, Michael Popp or Ina Thielmann depending on the respective 
mouse strain. 
 
2.2.2.2 Sample preparation for PCR 
The following pipetting scheme was used for all knock-out and double knock-out 
mouse strains described in this thesis for determination of genotype by PCR, 
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5µl 10x Taq buffer 
2µl DNA solution 
2µl dNTP solution (10µM) 
31.5µl H2O 
5µl MgCl2 (25mM) 
2µl primer 1 1:10 (stock: 1µg/µl) 
2µl primer 2 1:10 (stock: 1µg/µl) 
0.5µl Taq polymerase 
 
thus creating a final volume of 50µl for 1 sample. Genotyping was again kindly 
performed by Sebastian Dütting, Deya Cherpokova, Michael Popp, Ina 
Thielmann and lab technician Sylvia Hengst. 
 
2.2.2.3 Cdc42 floxed allele detection 
Primers 
Cdc42_for    
Cdc42_rev   
5’ ATG TAG TGT CTG TCC ATT GG 3’ 
5’ TCT GCC ATC TAC ACA TAC AC 3’ 
 
PCR program 
95°C 2:00 min  
   
95°C 0:30 min 
10x 
63°C 0:30 min 
(-1°C each cycle) 
72°C 0:45 min 
   
95°C 0:30 min 
35x 53°C 0:30 min 
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72°C 0:45 min 
   
72°C 4:00 min  
4°C storage  
 
Band sizes 
wt allele : 200 bp 
floxed allele : 300 bp 
 
2.2.2.4 PF4-Cre transgene detection 
Primers 
PF4-Cre_for 
PF4-Cre_rev 
5’ CCC ATA CAG CAC ACC TTT TG 3’ 
5’ TGC ACA GTC AGC AGG TT 3’ 
 
PCR program 
96°C 3:00 min  
   
94°C 0:30 min 
35x 58°C 0:30 min 
72°C 0:45 min 
   
72°C 3:00 min  
4°C storage  
 
Band sizes 
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wt  : missing 
PF-4 Cre+ : 450 bp 
 
2.2.2.5 G12 and G13 knock-out floxed allele detection 
Primers G12 floxed allele 
12INC  
1092R  
Neo B 
5’ GTG CTC ATC CTT CCT GGT TTC C 
5’ CGG GTC GCC CTT GAA ATC TGG 
5’ GGC TGC TAA AGC GCA TGC TCC 
 
PCR program 
94°C 5:00 min  
   
94°C 1:00 min 
36x 65°C 1:00 min 
72°C 2:00 min 
   
72°C 10:00 min  
4°C storage  
 
 
Band sizes 
wt allele : 441 bp (12INC + 1092R) 
floxed allele : 314 bp (12INC + NeoB) 
 
 
Primers G13 floxed allele 
13Seq1 
Lox3.2 
5’ GCA CTC TTA CAG ACT CCC AC 
5’ GCC ACA GAG GGA TTC AGC AC 
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PCR program 
95°C 5:00 min  
   
95°C 0:15 min 
39x 56°C 0:15 min 
72°C 2:30 min 
   
72°C 10:00 min  
4°C storage  
 
 
Band sizes 
wt allele : 400 bp 
floxed allele : 470 bp 
 
2.2.2.6 RhoF floxed allele detection 
Primers 
RhoF_for 
RhoF_rev 
5’ CGC GAT CCT CGA ACA TCT AT 3’ 
5’ GCC CTG GAA CTC ACT TTG TC 3’ 
 
PCR program 
95°C 5:00 min  
   
95°C 0:30 min 
35x 58°C 0:30 min 
72°C 0:45 min 
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72°C 5:00 min  
4°C storage  
 
 
Band sizes 
wt allele : 199 bp 
floxed allele : 242 bp 
 
2.2.2.7 RhoA floxed allele detection 
Primers 
JVH11_for 
JVH15_rev 
5’ AGC CAG CCT CTT GAC CGA TTT A 
5’ TGT GGG ATA CCG TTT GAG CAT 
 
PCR program 
94°C 2:00 min  
   
94°C 0:30 min 
35x 55°C 0:30 min 
72°C 0:30 min 
   
72°C 10:00 min  
4°C storage  
 
 
Band sizes 
wt allele : 297 bp 
floxed allele : 393 bp 
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2.2.3 Histology 
2.2.3.1 Organ dissection, processing and preservation 
Mice were quickly and deeply anesthetized with maximum concentrations of 
isoflurane under high flow and humanely euthanized by prompt cervical 
dislocation. Dead mice were pinned onto a polystyrene board in supine position 
for sectioning and femura were retrieved by longitudinal incision below the iliac 
crest. Femura were cleaned from soft tissue and immersed in 4% 
paraformaldehyde (PFA) in phosphate buffered saline (PBS) overnight. Femura 
were then put into a decalcifying buffer of 10% ethylenediaminetetraacetic acid 
(EDTA) in PBS for 1 week with the buffer being changed 3 times. Mice spleens 
were obtained by lateral incision below the edge of the left ribcage (Kocher’s 
incision). Spleens were left to incubate at 4% PFA in PBS as well. Subsequently, 
all organs were embedded in paraffin and cutting was performed using a Microm 
cool cut microtome (Thermo Scientific, Braunschweig, Germany), creating 3 µm 
thin sections. Sections were left to dry overnight and stored in histology boxes. 
 
2.2.3.2 Hematoxylin and eosin staining, read-out 
Dried sections were immersed in Xylol for 10 min twice, before being rehydrated 
in a descending alcohol dilution series of 100%, 90%, 80% and 70% for 30 sec 
respectively. Sections rested in deionized water for 2 min and were subsequently 
put in hematoxylin (Sigma, Schnelldorf, Germany) solution for 15 sec and left to 
stain under running tab water for 7 min. Eosin was prepared using a 1:10 dilution 
of Eosin G 0.5% (Roth, Karlsruhe, Germany) in ddH2O and one drop of 100% 
acetic acid. Sections were counterstained in the eosin solution for 90 sec and 
washed shortly in deionized water. Rehydration was carried out in an ascending 
alcohol series, compare above for concentrations and time length. Two final steps 
of Xylol immersion for 10 min followed and glass cover slips were mounted using 
Eukitt. Stained sections were left to dry overnight and stored appropriately. Two 
bone marrow/spleen sections and 20 visual fields per section were analyzed at 
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40x magnification, if not stated otherwise. 
 
2.2.4 Measurement of spleen weight 
Mice were anesthetized and put on a precision balance for measurement of total 
body weight. After dissection of spleens described in 2.2.3.1, spleens were 
carefully examined to exclude artificial tissue damage and loss by sectioning. 
Remaining adjoining tissue was removed by tweezers and spleens were likewise 
measured on a precision balance and related to respective body weight. 
 
2.2.5 Glycoprotein inhibition 
Antibodies used for GP blockade experiments were kindly adjusted to 1 mg/ml 
antibody in PBS with 0.2% BSA by lab technicians. 
For GPIIb/IIIa and GPV blockade, RhoA deficient mice were injected into the 
retroorbital plexus with 100 µg 4H5-Fab-fragments or 100 µg 89F12 antibody 
respectively on three consecutive days with femura being retrieved on day 5. 
Regarding Clec-2 and GPVI blockade, 100 µg 11E9 antibody was used for Clec-
2 and 100 µg of 98A3 antibody for GPVI inhibition. Injection was performed twice 
on day 1 and 3; dissection of bones followed on day 5. 
 
2.2.6 Platelet depletion 
Platelet depletion was performed by one-time injection of 100µg rat anti-mouse 
GPIba into the retroorbital plexus of mice. Circulating platelet counts were 
monitored by consecutive blood drawing (vol 50µl) for 10 days after treatment by 
a Sysmex KX-21N automated hematology analyzer (Sysmex Corp., Kobe, 
Japan). Bones were explanted 1 day or 10 days after antibody injection. 
 
2.2.7 Determination of platelet count and size 
Anesthetized mice were bled from the retroorbital plexus using microcapillaries 
(vol 50µl) and blood was collected into an Eppendorf tube containing 300µl 
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heparin (20 U/ml) in Tris-buffered saline (TBS). Platelet counts and sizes were 
established using a Sysmex KX-21N. 
 
2.2.8 Platelet preparation and washing 
Blood was drawn under isoflurane anesthesia by insertion of a heparinized 
microcapillary into the retroorbital plexus. At least 700µl of blood was collected 
into a tube containing 300µl heparin in TBS. Platelet rich plasma (prp) was 
obtained by twice centrifugation at 800 rpm for 5 min with the buffy coat and 
supernatant being transferred to a new tube each time. Washing of prp was 
performed by centrifugation at 2,800 rpm for 5 min in the presence of apyrase 
(0.02 U/ml) and prostacyclin (PGI2, 0.01 µg/ml). The platelet pellet was 
resuspended in Tyrode’s buffer without Ca2+ and washed a second time under 
equal conditions. After incubation of platelets at 37°C for 5 min, another washing 
step concluded platelet preparation and the final platelet pellet was resuspended 
in Tyrode’s buffer with Ca2+ and left to incubate at 37°C for 30 min before 
fluorescence activated cell sorting (FACS) analysis. 
 
2.2.9 Flow cytometry 
Basal surface glycoprotein (GP) expression levels were determined by staining 
samples whole blood with fluorophore-conjugated antibodies (see section 2.1.3.) 
for 15 min at room temperature (RT). The reaction was stopped by addition of 
500µl PBS. For GPIIb/IIIa and P-Selectin activation studies, the respective 
agonists were added to the washed-platelet suspension and left to incubate for 6 
min at 37°C and 6 min at RT, before halting the reaction by addition of 500µl PBS. 
FACS measurement was performed directly after using a FACSCalibur (Becton 
Dickinson, Heidelberg, Germany). For two-color stainings, the following listing 
provides an overview of settings: 
 
Detectors/Amps 
Parameter Detector Voltage 
P1 FSC E01 
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P2 SSC 380 
P3 Fl1 650 
P4 Fl2 580 
P5 Fl3 150 
 
Threshold 
Value Parameter 
253 FSC-H 
52 SSC-H 
52 Fl1-H 
52 Fl2-H 
52 Fl3-H 
 
Compensation 
Fl1 2.4% of Fl2 
Fl2 7.0% of Fl1 
Fl2 0% of Fl3 
Fl3 0% of Fl2 
 
2.2.10 Platelet spreading assay 
2.2.10.1 Platelet spreading on fibrinogen 
100 µl of human fibrinogen (Sigma) diluted in PBS (100µg/ml) was pipetted onto 
glass cover slips and slides were left to incubate in a damp chamber overnight at 
4°C. Cover slips were rinsed with sterile PBS and blocked with PBS 1% BSA at 
37°C for 2h. Washed platelets were obtained as described in 2.2.8 and aliquots 
of 0,3x106 plts/µl were produced. Platelets were left to incubate at 37°C for 30 
min. 
Glass cover slips were rinsed with sterile PBS multiple times before being 
ultimately washed with Ca2+-containing Tyrode's buffer. Platelets were then 
activated by addition of Thrombin (0.01 U/ml) and pipetted onto the designated 
glass cover slips to allow for spreading. After the respective time points (5 min, 
15 min and 30 min) were reached, spreading was halted by adding PBS 4% PFA. 
Glass slides were mounted onto the cover slips and platelet spreading was 
analyzed by a Zeiss Axiovert 200 inverted microscope (x100) using differential 
interference contrast (DIC) microscopy. Images were captured by a CoolSNAP-
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EZ camera (Visitron, Munich, Germany) using MetaVue online software and 
readout was conducted with the ImageJ cell counter plugin. 
 
2.2.10.2 Platelet spreading on von Willebrand Factor (vWF) 
Glass cover slips were coated with 200µl of polyclonal rabbit-α-human vWF-
antibody (A0082, DAKO) diluted in 50mM carbonate-bicarbonate buffer (1:500) 
and were incubated in a damp chamber at 4°C overnight. Cover slips were rinsed 
with PBS and blocking was conducted with PBS 3% BSA at 37°C for 2h. 
To obtain mouse plasma, wild-type mice were bled from the retroorbital plexus 
and blood was collected as described in 2.2.8. Blood was centrifuged at 2800 
rpm for 10 min, the supernatant transferred to a new tube and centrifuged at 
14000 rpm. Incubation of slides with mouse plasma for 2h at 37°C followed. 
Washed platelets were obtained as described in 2.2.8 and aliquots of 0,3x106 
plts/µl produced. Platelets were left to incubate at 37°C for 30 min before addition 
of integrilin (60 µg/ml) to the suspension and renewed incubation for 10 min. 
Glass cover slips were rinsed after incubation with sterile PBS multiple times and 
as a last step Tyrode's buffer with Ca2+. Platelets were then activated by addition 
of Ca2+-containing Tyrode's buffer and high-dose Botrocetin (50 U/ml) and 
pipetted onto the designated glass cover slips to allow for spreading. In case of 
the vWF spreading assay, time spans analyzed were 10 min, 20 min and 30 min. 
The reaction was stopped and platelets were analyzed as described in 2.2.10.1. 
 
2.2.11 Data analysis 
All data were explored for normality by Shapiro-Wilk test, including homogenous 
variances by Levene-test. Student’s t-test was performed when parametric 
conditions were fulfilled and variance was homogenous. The Welch-test 
(modified t-test) was used when unequal variances occurred. In case of GP 
blockade experiments, in-group comparisons were performed using the t-test for 
paired samples. Under non-parametric conditions, the Mann Whitney U-test was 
applied to test for statistical significant difference between two groups and exact 
significance was calculated (n<30 fulfilled). For comparison of more than two 
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groups, one-way analysis of variance (ANOVA) was used, followed by post-hoc 
Tukey-test. SPSS 23 (IBM SPSS Statistics, New York, USA) was used for 
statistical analysis. Results are displayed as mean ± SD and usually represent 
three individual experiments, if not stated otherwise. Knock-out and littermate 
wild-type mice were used for experiments, if not stated otherwise. 
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3. Results 
3.1 MK localization upon deficiency of different cytoskeletal 
regulatory proteins 
3.1.1. Findings from bone marrow and spleen sections of RhoA-/- mice  
3.1.1.1 RhoA-/- mice exhibit an altered distribution of MKs compared 
to the wild-type  
Upon platelet activation, the small GTPase RhoA plays a pivotal role in mediating 
shape change, the release of a- and dense granules and outside-in signaling 
through integrin aIIbb3. RhoA has also been identified as an important actor in 
the formation of focal adhesions during cell migration79. Platelet studies revealed 
a macrothrombocytopenia with upregulated megakaryopoiesis in the bone 
marrow (BM) in RhoA deficient mice18, but RhoA had not been studied in the 
highlight of MK migration or localization in the BM. 
Mice were created by crossing animals carrying a RhoA gene flanked by loxP 
sites – so-called floxed (fl) mice (RhoAfl/fl)232 – with transgenic mice expressing 
Cre recombinase downstream of the MK- and platelet-specific platelet factor 4 
(PF4) promoter233, leading to loss of the gene product. Floxed, PF4-Cre positive 
(RhoAfl/fl,PF4-Cre+/-) RhoA deficient mice are further referred to as RhoA-/- and 
RhoAfl/fl,PF4-Cre-/- as wild-type (wt) mice. 
Michael Popp kindly provided and genotyped RhoA-/- mice. Mice femura were 
harvested, decalcified, embedded in paraffin and then cut by microtome. 
Hematoxylin and eosin staining (HE staining) was performed and a microscopic 
readout of the localization of MKs of 20 visual fields per bone section conducted 
(see Materials and Methods chapter). MKs were assigned to the three groups 
intraluminal, adjacent to vessel wall (vessel wall) and stroma. 
Strikingly, RhoA-/- mice exhibited a significantly higher number of MKs inside of 
BM sinusoids and adjacent to the blood vessel as compared to wt MKs (Fig. 1). 
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In contrast, MKs were found only very rarely intraluminally in wt mice. Fig. 2 
depicts representative images of this so far unreported observation in RhoA-/- 
mice. The divergence in the percentage of intrasinusoidal MKs in the BM could 
potentially be explained by an increase in MK numbers in the BM of RhoA-/- mice, 
however, as Fig. 3 shows, no statistically significant difference was found in 
comparison to the wt. 
 
 
 
 
Fig. 1. Alterations of MK localization in the BM of RhoA-/- mice. (A) The table depicts the mean 
numbers of MKs per visual field resting intraluminally, adjacent to the vessel wall (vessel wall) 
and in the stroma of the BM for RhoA-/- and wt mice in total numbers. (B) Presentation of MK 
numbers as percentages for RhoA-/-  and wt. Representative experiment with n=7 (RhoA-/-) and 
n=8 (wt) mice. ** p < 0.01. 
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Fig. 2. Intraluminal localization of MKs in RhoA-/- mice. (A) Overview at 5x magnification: the 
left panel demonstrates preservation quality of the analyzed BM in both the RhoA-/- and the wt 
mice. Scale bar: 480 µm. (B) Close-up view at 40x magnification: the lower picture of the right 
panel displays representative pictures of RhoA-/- MKs within the lumen of well-preserved BM 
sinusoids. The upper picture provides a detailed view of comparable wt BM in which MK 
transmigration occurs much less frequently. Arrows depict MKs. Scale bar: 60 µm. 
 
 
 
 
Fig. 3. MK counts in the BM of RhoA-/- and wt mice are similar. Total counts of MKs correspond 
to the experiment depicted in Fig. 1, n=7 (RhoA-/-) and n=8 (wt) mice. 
 
This indicates a distinct and potentially defective compartmentalization of MKs in 
the BM in RhoA-/- mice which suggests RhoA is needed in physiological MK 
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localization or migration and might account at least in part for the markedly 
reduced platelet count observed in RhoA-/- mice18.  
 
3.1.1.2 MK number in the spleen is unaltered in RhoA-/- mice 
Another natural site of hematopoiesis and consequently megakaryopoiesis in 
mice is the spleen which is why investigation of potential distinct knock-out 
features in this organ was performed. Only the total number of MKs was 
determined, as an assignment of MK localization to the aforementioned three 
groups remained elusive by conventional microscopy owing to the fact of much 
smaller sinusoids and a very densely populated red pulp in the spleen. 
Fig. 4 shows that, while a trend towards increased MK numbers was observed in 
RhoA-/- mice, it did not reach a statistically significant difference. Notably, the 
overall spleen architecture and MK morphology was similar in RhoA-/- and 
corresponding wt mice (Fig. 5). 
 
 
 
 
Fig. 4. A trend towards increased MK numbers in spleens from RhoA-/- mice. The number of 
MKs per visual field in RhoA-/- mice is moderately increased, but not significantly different 
compared to the wt. Representative experiment with n=8 mice per group. 
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Fig. 5. Similar MK counts in RhoA-/- and wt spleens. (A) Left panel, overview at 5x 
magnification: RhoA-/- and wt mice exhibit no obvious morphological differences regarding 
configuration of the organ as a whole and the red pulp. Scale bar: 480 µm. (B) Right panel, close-
up view at 40x magnification: observed MKs were similar in size and morphology. Arrows depict 
MKs. Scale bar: 60 µm. 
 
These findings point out that MK localization in the spleen is not obviously 
affected by the knock-out of RhoA. They also indicate that there is no major shift 
of megakaryopoiesis from the BM to the spleen as a secondary site of 
hematopoiesis, owing to the macrothrombocytopenia reported in RhoA-/- mice. 
 
3.1.2 Increased MK counts in the BM and the spleen of RhoA/Cdc42-/- mice 
Cdc42-/- single knock-out mice display mild macrothrombocytopenia which is 
associated with a decreased platelet life span149. Circulating platelet numbers 
and megakaryocytic replenishment are linked by a negative feedback loop to be 
kept in a steady-state234. Cdc42-/- mice also exhibit higher MK numbers in the BM. 
In addition, Cdc42-/- MKs derived from murine fetal liver cells showed impaired 
proplatelet formation which was even more pronounced upon Rac1/Cdc42 
double-deficiency, revealing redundant functions of these two GTPases in 
platelet production52. To investigate whether also RhoA and Cdc42 might have 
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overlapping function in MK localization or migration, MK numbers were analyzed 
in BM and spleen of RhoA/Cdc42-/- mice. Deya Cherpokova generously provided 
and genotyped mice for the following experiments. 
Due to insufficient preservation of BM sinusoids in this mouse strain, 
compartmental read-out was not possible to conduct and thus only overall MK 
counts were established. RhoA/Cdc42-/- mice exhibited significantly higher 
numbers of MKs in the BM than wt mice, in line with results of the Cdc42-/- single 
knock-out (Fig. 6). This may be the result of an upregulation in megakaryopoiesis 
in response to the observed thrombocytopenia. The overall morphology of 
RhoA/Cdc42-/- and wt MKs was similar (Fig. 7). 
 
 
 
 
Fig. 6. RhoA/Cdc42-/- mice have increased MK numbers in the BM. The BM of RhoA/Cdc42-/- 
mice contains more MKs compared to the wt. Representative experiment with n=4 mice per group. 
* p < 0.05. 
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Fig. 7. BM comparison of RhoA/Cdc42-/- with wt mice. (A) The left panel displays an overview 
at 5x magnification of both RhoA/Cdc42-/- and wt BM. Scale bar: 480 µm. (B) The right panel with 
a closer view at 40x magnification of both RhoA/Cdc42-/- and wt MKs. Sinusoid preservation was 
not sufficient for compartmental read-out. RhoA/Cdc42-/-  MKs do not show an altered morphology 
compared to their wt counterparts. Arrows depict MKs. Scale bar: 60 µm. 
 
Interestingly, splenic MK numbers were strongly increased in RhoA/Cdc42-/- mice 
and exceeded wt counts threefold (Fig. 8). No observable changes neither 
concerning spleen architecture nor MK morphology could be observed compared 
to the wt. Representative images of spleen sections are depicted in Fig. 9. 
 
 
 
Fig. 8. RhoA/Cdc42-/- mice display drastically increased counts of MKs in the spleen. The 
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sum of MKs in RhoA/Cdc42-/- mice is greatly increased related to wt mice. Representative 
experiment with n=4 mice per group. * p < 0.05. 
 
 
 
 
Fig. 9. Spleen architecture and MK morphology are similar in RhoA/Cdc42-/- compared to 
wt mice. (A) Overview of spleens at 5x magnification does not see a major difference in setup 
regarding, e.g. organ shape or the red pulp/ white pulp ratio between RhoA/Cdc42-/-  and wt mice. 
Scale bar: 480µm. (B) The right panel at 40x magnification shows a similar phenotype of 
RhoA/Cdc42-/- and wt MKs. Arrows depict some MKs. Scale bar: 60 µm. 
 
Having observed drastically elevated MK counts in RhoA/Cdc42-/- spleens, total 
spleen weight was measured to check for splenomegaly as a sign of a shift of 
megakaryopoiesis from the bone marrow to this site of secondary hematopoiesis. 
Indeed, spleen weight of RhoA/Cdc42-/- mice was increased by 30% compared 
to wt counterparts, compare Fig. 10, indicating a mild splenomegaly. 
Although this study lacks the inclusion of Cdc42-/- mice to be compared with 
RhoA-/- and RhoA/Cdc42-/- mice, together these findings support the observation 
that the defect thrombopoiesis is considerably aggravated upon RhoA/Cdc42 
double-deficiency compared to single-deficiency of either RhoA or Cdc42. 
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Fig. 10. RhoA/Cdc42-/- mice show increased spleen weight. RhoA/Cdc42-/- mice compared to 
wt mice display a significantly increased her spleen weight, indicating a shift of megakaryopoiesis 
to this secondary hematopoietic organ. Results are given as spleen weight/ body weight of the 
respective mice. Representative experiment with n=4 mice per group. ** p < 0.01. 
 
3.1.3 Analysis of MK localization in BM of G12/13 double knock-out mice 
Signaling through the G12 and more importantly G13 protein is one of the two major 
axes of RhoA activation. RhoA can also be activated downstream of Gq protein-
mediated signaling, especially in the setting of high agonist doses155. In platelets, 
G12 and G13 of the stimulating type Gs are activated downstream of protease 
activated receptors (PARs) and the thromboxane-prostanoid (TP) receptor upon 
stimulation with agonists, e.g. thrombin, thromboxane A2 (TxA2) and the TxA2 
mimetic U-46619 (U-46)154,155. 
A mouse strain double deficient of G12 and G13 (encoded by the genes Gna12 
and Gna13) was used to investigate whether RhoA activation/signaling might 
also involve these G proteins in MKs. Mice were generously provided and 
genotyped by Ina Thielmann. Notably, however, the MK phenotype of RhoA-/- 
mice was not observed in G12/13-/- mice resulting in unaltered MK distributions in 
the BM compared to the wt (Fig. 11). 
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Fig. 11. G12/13-/- mice and their wt counterparts show a similar MK distribution in the BM. 
Representative experiment with n=3 (G12/13-/-) and n=2 (wt) per group. 
 
Studies of the total numbers of MKs in the BM were performed as well and 
showed a similar number of MKs in mice from both genotypes (Fig. 12). It has to 
be noted though that the genetic background and the knock-out strategy of mice 
were different in G12/13-/- mice, compared to RhoA-/- mice with creation of a Gna13 
allele, Gna13ta which contains three loxP sites, along with a cassette of the 
neomycin resistance (neor) and thymidine kinase gene (tk). After conversion into 
a floxed allele (Gna13flox), mice were crossed with the Cre-deleter mouse strain 
EIIa-Cre to allow generation of a Gna13- null allele154. 
 
 
 
Fig. 12. Total MK numbers in the BM are similar in G12/13-/- and wt. Representative experiment 
with n=3 (G12/13-/-) and n=2 (wt) mice per group. 
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Fig. 13. BM and MK morphology are identical in G12/13-/- and wt mice. (A) Overview at 5x 
magnification shows the configuration of the BM for G12/13-/- and wt mice respectively. Scale bar: 
480 µm. (B) Close up-view at higher magnification (40x) for analysis of MK morphology yielding 
no obvious divergence in structure. Arrows depict MKs. Scale bar: 60 µm.  
 
No substantial difference in BM architecture or MK morphology could be 
observed during analysis of the BM sections (Fig. 13). In line with these 
observations, MK numbers and spleen architecture were similar in spleen 
sections from G12/13-/- mice and wt mice (Fig. 14, 15.) 
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Fig. 14. Spleens of G12/13-/- and wt mice display similar MK numbers. Representative 
experiment with n=3 mice per group. 
 
 
 
 
Fig. 15. G12/13-/- mice do not show an altered spleen morphology. (A) Upper panel at 5x 
magnification demonstrates comparable organ morphology of G12/13-/- and wt mice. Scale bar: 480 
µm. (B) Lower panel depicts a close-up view at 40x magnification of the spleen architecture. No 
MKs visible on this picture. Scale bar: 60 µm. 
 
Together, these results show that G12/13-/- mice do not reproduce the MK 
phenotype observed in the RhoA knock-out, suggesting RhoA-controlled MK 
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compartmentalization takes place independently of signaling through G12 and G13 
proteins. 
 
3.2. Investigation of signaling pathways involving RhoA in MKs 
3.2.1 GPIb-mediated platelet depletion and effects on MK localization in 
RhoA-/- mice 
3.2.1.1 Findings one day after platelet depletion in RhoA-/- mice 
The finding that the RhoA-/- phenotype shows a significantly higher percentage of 
intraluminal MKs entails the question which signaling events might contribute to 
that phenomenon. First, investigation of megakaryopoiesis under stress was 
conducted by antibody mediated platelet depletion in order to assess possible 
influences. Michael Popp kindly provided, genotyped and performed antibody 
injection on the mice. Depletion was achieved by injection of polyclonal rat anti-
mouse GPIb antibody binding to circulating platelets and leading to consecutive 
clearance from the blood stream. Preservation and analysis of bone marrow 
sections was carried out as laid out before.  
Compartmentalization readout had to be omitted due to technical difficulties 
which is why only total numbers of MKs were established. As Fig. 16 shows, 
femura of RhoA-/- mice harvested one day after (t=1d) platelet depletion showed 
no alteration in their MK counts compared to the wt. Likewise, MK morphology 
was similar as compared to BM from the respective non-treated genotype (Fig. 
17). 
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Fig. 16. GPIb antibody injected RhoA-/- mice show comparable MK numbers on t=1d. BM of 
RhoA-/- mice one day after antibody injection (t=1d) exhibit similar MK numbers compared to the 
wt. Single experiment with n=4 mice per group. 
 
 
 
 
Fig. 17. Unaltered MK morphology in RhoA-/- mice one day after antibody. (A) Left and (B) 
right panels from different animals with close-up views at 40x magnification detail similar 
morphology of MKs of RhoA-/- and wt mice one day after GPIb antibody injection and platelet 
depletion. Arrows depict MKs. Scale bar: 60 µm. 
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Fig. 18. Antibody injection of RhoA-/- mice leaves counts of MKs unaltered in the spleen 
after one day. GPIb mediated platelet depletion of RhoA-/- and wt mice yield comparable MK 
numbers one day (t=1d) after injection. Single experiment with n=4 mice per group. 
 
In line with this, splenic MK numbers were similar in RhoA-/- and wt mice, see Fig. 
18. Also MK morphology in the spleen was not affected by sustained 
megakaryopoietic stress (Fig. 19). 
 
 
 
Fig. 19. Spleens of platelet-depleted RhoA-/- and wt mice exhibit similar architecture. Both 
panels (A) and (B) depicting RhoA-/- and corresponding wt MKs at a high magnification (40x) in 
the spleen. Arrows depict MKs. Scale bar: 60 µm. 
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These findings illustrate that short-term stress on megakaryopoiesis does not 
become visible in a change of MK numbers in the bone in either RhoA-/- or wt 
mice. 
  
3.2.1.2 Similar recovery of MK counts in RhoA-/- and wt mice at day 
10 after platelet depletion 
Analysis of BM sections from RhoA-/- mice 10 days after platelet depletion was 
performed in order to investigate longer term effects on MKs. At this time point, 
experiments by Michael Popp showed that the platelet numbers in both RhoA-/-  
and wt mice had returned to their original levels, respectively (data not shown). 
In this experiment, RhoA-/- mice exhibited results similar to the phenotype of wt 
mice 10 days after platelet depletion with regard to total MK numbers in the BM 
(Fig. 20). Studied sections of bone marrow did not show an altered architecture 
of the bone marrow itself, nor at the cellular level regarding MKs (Fig. 21). 
 
 
 
 
Fig. 20. RhoA-/- and wt mice do not show increased totals of MKs at t=10d after platelet 
depletion. (A) MK numbers in platelet-depleted RhoA-/- and wt mice are comparable to one 
another. (B) Comparison of RhoA-/- and wt mice at t=10d with untreated mice exhibits similar 
results. Data for control group taken from experiment depicted in Fig. 2. Single experiment with 
n=6 mice per group. 
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Fig. 21. Bone marrow sections of RhoA-/- and wt mice obtained at day 10 after platelet 
depletion show similar morphology. (A) An overview at 5x magnification does not reveal major 
differences between RhoA-/- (t=10d) and the wt (t=10d) regarding BM structure. Scale bar: 480µm. 
(B) Detailed view at 40x magnification: RhoA-/- and wt MKs exhibit similar morphologies. Arrows 
depict MKs. Scale bar: 60 µm. 
 
Examination of the spleen was additionally performed in order to investigate 
potential changes elsewhere in the murine hematopoietic system. Comparison of 
antibody-injected RhoA-/- and wt mice revealed no divergence in MK numbers in 
this organ, neither regarding organ architecture, nor MK appearance (Fig. 22, 23). 
Together, these findings indicate that RhoA does not play a major role for the 
recovery of megakaryopoiesis under acute stress. 
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Fig. 22. MK numbers are on an equal level 10 days after antibody injection in RhoA-/- and 
wt mice spleens. RhoA-/- and wt spleens exhibit similar counts of MKs in the spleen (t=10d) after 
GPIb antibody injection. Single experiment with n=6 mice per group. 
 
 
 
Fig. 23. Comparable spleen morphology 10 days after platelet depletion in RhoA-/- and wt 
mice. (A) Left panel depicting spleen morphologies at a lower magnification (5x) of both RhoA-/- 
(t=10d) and wt (t=10d) mice. Scale bar: 480 µm. (B) Right panel with a detailed view (40x 
magnification) of MK morphology in the spleen. Arrows depict MKs. Scale bar: 60 µm. 
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3.2.2 Effect of blockade of important MK surface receptors on MK 
localization in RhoA-/- mice 
3.2.2.1 Integrin aIIbb3 blockade does not alter MK 
compartmentalization in RhoA-/- mice 
Integrin aIIbb3 is instrumental in platelet activation and mediates a great variety 
of effects required for physiological hemostasis such as firm adhesion to the ECM 
and cross-linking of platelets to allow a growing platelet plug. Functioning as 
adhesion molecules32,87, MKs might likely depend on their function during BM 
egress from the stroma towards the lumen of BM sinusoids. 
Therefore, investigation of the effect of in vivo blockade of integrin aIIbb3 was 
conducted with special focus on the intraluminal compartment, being best 
accessible and susceptible to antibody injection. 
RhoA-/- and wt mice were injected intravenously (i.v.) into the retroorbital plexus 
three times with 100µl of 4H5 F(ab)2 fragments (IgG2b) on consecutive days and 
bones were harvested on day 5. Michael Popp kindly provided, genotyped and 
injected mice according to protocol. 
Analysis of integrin aIIbb3 blocked-RhoA-/- (RhoA-/- 4H5 F(ab)2) mice showed that 
the RhoA knock-out phenotype was preserved and a significantly higher number 
of MKs were located intraluminally and adjacent to the endothelial lining of BM 
sinusoids compared to likewise treated wt (wt 4H5 F(ab)2), see Fig. 24. 
Stimulating effects on megakaryopoiesis could not be observed, as total numbers 
of MKs remained constant compared with non-injected RhoA-/- and wt mice (Fig. 
25). Consistently, histological study of the BM of the dissected femura did not 
reveal an alteration in BM architecture (Fig. 26). 
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Fig. 24. MKs of RhoA-/- 4H5 F(ab)2 mice show similar compartmentalization as compared to 
RhoA-/- mice. (A) MKs of RhoA-/- 4H5 F(ab)2 mice rest intraluminally and adjacent to the vessel 
wall more often than in the stroma related to wt 4H5 F(ab)2 mice. (B) Percentagewise depiction of 
MKs for better comparison. Single experiment with n=4 mice per group (RhoA-/-/wt 4H5 F(ab)2). 
*** p < 0.001, ** p < 0.01. 
 
 
 
 
 
Fig. 25. Total numbers of MKs of 4H5 F(ab)2-injected RhoA-/- and wt mice are comparable 
to non-injected mice. (A) Depiction of RhoA-/- and wt mice receiving antibody-mediated integrin 
aIIbb3 blockade. Similar MK counts were found in both groups. (B) Comparison of 4H5 F(ab)2-
injected mice to non-injected RhoA-/- and wt mice. Data for RhoA-/- mice are taken from Fig. 2. n=4 
mice per group (RhoA-/-/wt 4H5 F(ab)2). 
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Fig 26. BM architecture and MK morphology is similar in RhoA-/- 4H5 F(ab)2 and treated wt 
mice. (A) 5x magnified overview of BM sections does not reveal differences in morphology of 
integrin aIIbb3-attenuated RhoA-/- and wt mice. Scale bar: 480µm. (B) Close-up view at 40x 
magnification shows unaltered MK structure for injected RhoA-/- and wt mice. Arrows depict some 
MKs. Scale bar: 60 µm. 
 
Although of major importance in platelet signaling, blockade of integrin aIIbb3  did 
not lead to changes in the phenotype of RhoA-/- mice with regard to MK 
localization in the BM. Thus integrin aIIbb does not seem to be required for 
neither the transmigration of deficient MKs into BM sinusoids, nor the adhesion 
to the vessel wall once inside. 
 
3.2.2.2 Blockade of GPVI does not substantially alter intraluminal 
localization of RhoA-/- MKs 
Glycoprotein VI (GPVI) is the central platelet collagen receptor235 which might 
also indicate a role for GPVI in MK interaction with elements of the extracellular 
matrix. To address the effects of a GPVI blockade, RhoA-/- and littermate wt mice 
were injected with 100µl of JAQ-1 IgG2a antibody on day 1 and 3. Mice were 
generously provided, genotyped and injected by Michael Popp. 
Although no statistical significant difference in intraluminal MKs could be 
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observed in RhoA-/- GPVI blocked (RhoA-/- JAQ-1) mice compared to likewise 
treated wt JAQ-1 mice, the phenotype of an increased number of MKs inside of 
BM sinusoids persisted. Taking into account the stromal and vessel-wall adjacent 
distribution of MKs, it can be concluded that GPVI blockade does not influence 
the ability of RhoA-/- to transmigrate into BM sinusoids (Fig. 27). An effect of GPVI 
blockade on total MK numbers in the BM could not be found (Fig. 28). 
Furthermore, BM examination showed no obvious alterations in MK morphology 
(Fig. 29). 
 
 
 
 
Fig. 27. JAQ-1-treated RhoA-/- and wt mice display similar levels of intraluminal MKs. (A) 
BM sections of JAQ-1-injected RhoA-/- and wt mice show a similar distribution of MKs, compared 
to non-injected RhoA-/- and wt mice with intraluminal and vessel-adjacent populations being 
increased under RhoA-/- conditions. (B) Percentagewise depiction of MKs for better comparison. 
Data for RhoA-/- mice are taken from Fig.2. Single experiment with n=3 (RhoA-/- JAQ-1) and n=4 
(wt JAQ-1) per group. ** p < 0.01, * p < 0.05. 
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Fig. 28. Total MK numbers in BM of RhoA-/- JAQ-1 and injected wt mice are similar. (A) 
RhoA-/- JAQ-1 and wt JAQ-1 mice exhibit no significant difference in MK numbers. (B) The BM of 
RhoA-/- JAQ-1 and comparable wt mice contains a similar number of MKs compared to non-
injected mice. Data for RhoA-/- mice are taken from Fig. 2. n=3 (RhoA-/- JAQ-1) and n=4 (wt JAQ-
1) mice per group. 
 
 
 
Fig. 29. Histological evaluation of RhoA-/- JAQ-1 and injected wt mice exhibit physiological 
phenotypes. (A) Overview at 5x magnification displays BM morphology for both RhoA-/- JAQ-1 
and wt JAQ-1 mice. Scale bar: 480 µm. (B) Detailed view at 40x magnification showing regularly 
configured MKs in GPVI blocked mice. Arrows depict MKs. Scale bar: 60 µm. 
 
These findings suggest that transmigration and adherence to the vessel wall of 
MKs happens independently of GPVI and might involve signaling through 
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different receptors and ECM proteins. 
 
3.2.2.3 Blockade of the Clec-2 receptor does not have a major 
influence on MK compartmentalization in RhoA-/- mice 
The C-type lectin-like receptor 2 (Clec-2) is physiologically activated by 
podoplanin and has been studied with regard to antithrombotic and antimetastatic 
therapy in hematology and cancer medicine236. Signaling occurs through a hemi 
immunoreceptor tyrosine-based activation motif (ITAM) and is hereby similar to 
GPVI-mediated signaling via the double YxxL ITAM. 
Analogous to injection of a GPVI depleting antibody, treatment with the INU1 
antibody results in the transient loss of the Clec-2 receptor from the platelet and 
MK surface, yielding a knock-out like phenotype. 
Both RhoA-/- and wt mice were injected with 100µl INU1 (IgG1) antibody on days 
1 and 3 with bone dissection following on day 5. Michael Popp kindly provided, 
genotyped and injected mice according to protocol. 
RhoA-/- INU1 mice showed slightly non-significantly increased numbers of 
intraluminal MKs, while MKs adjacent to the vessel wall were significantly 
increased compared to injected wt INU1 mice, reproducing the results of the 
RhoA-/- JAQ1 mice (Fig. 30). The total number of MKs in BM sections of RhoA-/- 
INU1 mice differed from non-injected RhoA-/- mice, as they exhibited a higher 
number of MKs (Fig. 31). Morphology of the analyzed BM and MKs were not 
found to diverge in RhoA-/- INU1 and likewise treated wt mice (Fig. 32). 
 
 
 65 
 
 
Fig. 30. RhoA-/- and wt INU1 mice exhibit similar numbers of intraluminal MKs in the BM. 
(A) RhoA-/- INU1 and wt INU1 controls do not differ from in intraluminal MK localization from their 
untreated counterparts. Vessel wall MKs were thus increased in RhoA-/- INU1 mice, whereas the 
stromal population was elevated in the wt INU1 mice. (B) Depiction as percentages for better 
comparison. Single experiment with n=5 (RhoA-/- INU1) and n=6 (wt INU1) mice per group. * p < 
0.05. 
 
 
 
 
Fig. 31. The total number of MKs of RhoA-/- INU1 and antibody-treated wt mice in the BM is 
equal, but totals of RhoA-/- INU1 mice were higher compared to non-treated mice. (A) 
Blockade of the Clec-2 receptor does not lead to different MK levels in RhoA-/- INU1 and wt INU1 
mice. (B) Attenuation of Clec-2 leads to an increase of MK totals in the BM of RhoA-/- mice, 
compared to uninjected RhoA-/- mice. Data for RhoA-/- mice are taken from Fig. 2. n=5 (RhoA-/- 
INU1) and n=6 (wt INU1) mice per group. * p < 0.05. 
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Fig. 32. BM sections reveal similar morphology of RhoA-/- INU1 and injected wt mice. (A) 
Left panel depicts an overview at 5x magnification exhibiting equal BM structure of RhoA-/- INU1 
and corresponding wt INU1 mice. Scale bar: 480µm. (B) Right panel with a higher magnification 
(40x) highlighting comparable MK morphology between the injected mice. Arrows depict MKs. 
Scale bar: 60 µm. 
 
In summary, these results show that after blockade of the Clec-2 receptor the 
compartmentalization effect of RhoA deficiency is unaltered and therefore 
suggests signaling through (hem)ITAM-independent pathways. With respect to 
MK numbers in the BM, blockade of Clec-2 has a slight effect in terms of an 
increase of total numbers of MKs in RhoA-/- mice, although this needs to be 
validated in further experiments with introduction of a non-injected control group. 
 
3.2.2.4. Blockade of GPV in RhoA-/- mice does not affect 
compartmentalization deficit of MKs in the BM 
GPV is closely associated with the GPIb-IX complex through a transmembrane 
domain and takes part in GPIb-mediated signaling in the presence of von 
Willebrand factor (vWF), thrombin or factors XI and XII237. The GPIb-IX-V 
receptor complex mediates adhesion of platelets during coagulation and 
therefore might be of importance already during migration and adhesion of MKs 
in the BM. In this regard, defective GPV could constitute signaling changes which 
 67 
is why GPV antibody-injected RhoA-/- (RhoA-/- 89F12) and comparable wt (wt 
89F12) mice were investigated accordingly. 
Mice were kindly provided, genotyped and injected by Michael Popp. On day 1 
through 3, 100µl of DOM1/89F12 (IgG2a) antibody were injected into the 
retroorbital plexus and dissection of bones was performed on day 5. 
Compartmentalization analysis of RhoA-/- 89F12 resulted in a significant increase 
in vessel wall adjacent MKs in RhoA-/- 89F12 mice. In addition, the intraluminal 
population was higher in GPV antibody-treated RhoA-/- than in equally injected wt 
mice, whereas the stromal population was lower (Fig. 33). Of note, total numbers 
of MKs in the BM were increased in RhoA-/- 89F12 compared to treated wt mice, 
whereas MK counts were on a comparable level between injected wt and non-
injected mice (Fig. 34). Analysis of BM sections and MKs did not show altered 
architecture and MK morphology in RhoA-/- 89F12 or equally injected wt mice (Fig. 
35). 
 
 
 
 
Fig. 33. RhoA-/- 89F12 mice and antibody-injected wt controls differ in the totals of MKs 
adjacent to the vessel wall. (A) The table depicts the number of MKs in the GPV blockade 
condition for RhoA-/- 89F12 and wt 89F12 mice respectively, according to BM compartment. 
Counts are significantly different in MKs adjacent to the vessel. (B) Percentagewise depiction for 
better comparison. Single experiment with n=3 (RhoA-/- 89F12) and n=4 (wt 89F12) mice per 
group. * p < 0.05. 
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Fig. 34. RhoA-/- 89F12 mice show increased MK numbers compared to equally treated wt 
mice. (A) Total counts of MKs were found to be higher in RhoA-/- 89F12 mice than equally injected 
wt 89F12 mice. (B) MK numbers were on a comparable level with untreated mice. Data for RhoA-
/-
 mice are taken from Fig. 2. n=3 (RhoA-/- 89F12) and n=4 (wt 89F12) mice per group. * p < 0.05. 
 
 
 
 
Fig. 35. BM structure and MK morphology are not affected by injection of GPV antibody in 
RhoA-/- and wt mice. (A) Overview at 5x magnification displays equivalent BM configuration of 
both injected RhoA-/- 89F12 and corresponding wt 89F12 mice. Scale bar: 480µm. (B) Close-up 
view at 40x magnification depicts unaltered MK morphology between RhoA-/- 89F12 and wt 89F12 
mice. Arrows depict MKs. Scale bar: 60 µm. 
 
Together RhoA-/- 89F12 mice show a similar phenotype as observed in non-
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treated RhoA-/- mice, but GPV blockade in RhoA-/- mice might lead to a moderate 
increase in megakaryopoiesis. This finding needs to be validated in subsequent 
studies including a control group. 
 
3.3 Characterization of the role of RhoF deficient in platelets 
using conditional knock-out mice 
The small GTPase RhoF has been a more recent addition to the Rho family of 
small GTPases and it is presumed to play a role in filopodia formation156. There 
is evidence that RhoF-generated filopodia are longer and thinner than filopodia 
induced by Cdc42, raising the questions if different subtypes of filopodia exist70,123. 
Aim of this study was to characterize the role of RhoF in platelets to complement 
recently published results161 and to study RhoF-/- platelets extensively in their 
behavior regarding filopodia formation. For this purpose, mice containing loxP 
sites introduced into the RhoF gene (RhoFfl/fl) were successfully generated and 
crossed with PF-4 Cre transgenic mice, creating RhoFfl/fl,PF-4Cre+/- (further referred 
to as RhoF-/-) mice, thereby eliminating RhoF expression in MKs and platelets. 
Mice were kindly provided and genotyped by Sebastian Dütting and Sylvia 
Hengst.  
 
3.3.1 Analysis of platelet activation in RhoF-/- mice by flow cytometry 
3.3.1.1 Platelet count and size and glycoprotein expression in RhoF-/- 
and wt mice 
Flow cytometric and Sysmex® analysis of RhoF-/- platelets showed ko and wt 
platelets were similar in count and size (data not shown). 
These findings suggest that megakaryopoiesis is not affected in RhoF-/- 
deficiency. This was later supported by investigation of the platelet life span in 
vivo which was found to be unaltered in RhoF-/ mice compared to the wt161. 
Differences in glycoprotein surface expression levels have to be considered in 
diverging signaling responses upon agonist stimulation in platelets. To address 
this issue, GP expression in RhoF-/- platelets was studied. Components of the 
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GPIb-IX-V complex were similar in quantitative expression in RhoF-/- platelets 
compared to the wt. Glycoprotein CD9 also exhibited same expression levels in 
both groups. Integrins aIIbb3, a2 and b1 were neither found to differ in the knock-
out nor the wt, constituting regular integrin expression in RhoF-/- mice. The 
collagen receptor GPVI and Clec-2 receptor were equally expressed in RhoF-/- 
and wt mice (Fig. 36). In summary, RhoF deficiency was not associated with 
altered platelet surface receptor expression levels. 
 
 
 
Fig 36. Expression of important platelet surface receptors as determined by flow cytometry. 
No alterations could be found between RhoF-/- and wt mice for all glycoproteins. Results depicted 
as means ± SD. Representative experiment with n=4 mice per group. 
 
3.3.1.2 Unaltered integrin aIIbb3 activation in RhoF-/- platelets 
Measurement of platelet activation in RhoF-/- mice was conducted through 
evaluation of levels of active integrin aIIbb3 levels upon agonist stimulation, with 
integrin aIIbb3 constituting the most abundant platelet integrin238,239. 
Platelet activation assays showed no major difference in RhoF-/- platelets 
compared to the wt in integrin aIIbb3 activation. Upon stimulation with the 
agonists ADP and the TxA2 mimetic, U-46619 (U-46) RhoF-/- and wt platelets 
showed only moderate signs of activation, visible in a slight increase in mean 
fluorescence intensity (MFI). ADP and U-46 combined function as a strong 
activator of platelets, but no differences in the response of RhoF-/- and wt platelets 
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were observed. Thrombin signaling, irrespective of the used concentration, was 
likewise found to be unaltered in both RhoF-/- compared to wt platelets. Taken 
together, activation of RhoF-/- platelets through G13 and Gq receptors seems 
unaltered. Epinephrine as an agonist of the Gz receptor did not induce different 
responses in RhoF-/- and wt platelets either. ITAM and (hem)ITAM mediated 
pathways of platelet activation represented by signaling via the agonists collagen-
related peptide (CRP), convulxin (CVX) and rhodocytin (RC) overall elicited a 
higher response in RhoF-/- than wt platelets for almost all tested concentrations 
(Fig. 37), but this finding could not reproduced in following experiments, 
suggesting technical problems in the activation setting with the wt. Therefore, we 
conclude that these results indicate that RhoF deficiency has no impact on 
platelet activation, at least under in vitro conditions. 
 
 
Fig. 37. Integrin aIIbb3 activation assay shows comparable results in RhoF-/- and wt mice. 
Signaling through major platelet receptors is similar and also unaffected by concentration in RhoF-
/- platelets. Binding of JON/A-PE antibody constitutes mean fluorescence intensity (MFI). Results 
presented as means ± SD. n=4 mice per group. 
  
3.3.1.3 a granule release is not impaired in RhoF-/- platelets 
Another component of great significance in platelet activation is the ability to 
release stored granules, thereby sustaining platelet activation through autocrine 
signaling87. Investigation of a granule release can be studied by assessment of 
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P-Selectin levels, as it can be found on platelet a granules18. Granule release is 
mediated by fusion of platelet granules with the platelet surface membrane, thus 
making P-Selectin accessible for antibody binding and subsequent analysis by 
flow cytometry. 
P-Selectin surface exposure as a marker of degranulation effectiveness upon 
stimulation was shown to be equal in RhoF-/- and wt platelets, regarding ADP, U-
46 or combined stimulation. Thrombin stimulation yielded comparable results for 
knock-out and wt mice at all studied concentrations and precludes major defects 
in G13 and Gq signaling. Stimulation with the agonists CRP, CVX and RC through 
receptors GPVI and Clec-2 exhibited similar results in both groups. Finally, also 
Gz signaling assessed by the weak agonist epinephrine completed analysis of 
degranulation potency and was unaltered in both RhoF-/- and wt platelets (Fig. 
38). 
 
 
Fig. 38. Granule release is fully functional in RhoF-/- mice. P-Selectin exposure as a marker 
for platelet degranulation is equal in knock-out and wt mice, precluding signaling defects in major 
platelet receptors and is not affected by concentrations of the studied agonists either. Binding of 
anti P-Selectin-FITC antibody constitutes mean fluorescence intensity (MFI). Results given as 
means ± SD. n=4 mice per group. 
 
The findings of sections 3.3.1.2 and 3.3.1.3 suggest that RhoF is dispensable in 
platelet activation and granule release in response to agonist stimulation, 
reproducing results of a similar study161. 
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3.3.2 Platelet spreading of RhoF-/- mice evaluated by two different agonists 
3.3.2.1 RhoF-/- platelets spread normally on fibrinogen 
The extracellular matrix component and agonist surface fibrinogen is commonly 
used to assess platelet spreading. Fibrinogen is recognized by integrin aIIbb3 
and induces outside-in signaling leading to cytoskeletal rearrangements 
necessary for platelet spreading240,241. RhoF has been proposed to be essential 
for filopodia formation in various cell lines. 
To investigate a potential involvement of RhoF in platelet spreading, RhoF-/- and 
wt platelets were allowed to adhere to and spread on fibrinogen-treated glass 
cover slips and studied at three different time points upon thrombin stimulation. 
RhoF-/- platelets were found to spread similarly in comparison to their wt 
counterparts at all studied time points. Most interestingly, filopodia formation was 
not impaired in RhoF-/- platelets (Fig. 39). 
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Fig. 39. Spreading of platelets on fibrinogen is unaffected by knockout of RhoF. (A) RhoF-
/- and wt platelets spread similarly on fibrinogen at 5 min, 15 min and 30 minutes. Upon activation, 
platelets start forming filopodia, later lamellipodia, before they become fully spread. 
Representative images of wt and RhoF-/- platelets. Scale bar: 5 µm. (B) Results are displayed as 
stacked bars representing the mean percentage of platelets in each spreading phase. Notably, 
filopodia formation is not impaired in RhoF-/- platelets. Phase1: Unspread platelets, phase 2: 
filopodia formation, phase 3: lamellipodia formation, phase 4: fully spread platelets. 
Representative experiment with n=3 mice per group. 
 
3.3.2.2 Adhesion of RhoF-/- platelets on immobilized vWF is similar to 
the wt 
vWF binds to the GPIb-IX-V complex and this interaction helps platelets adhere 
at sites of vessel injuries, especially under high-shear conditions239. Platelet 
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spreading on immobilized vWF is attenuated with platelets only reaching the 
filopodial stage of spreading242. By use of this method subtle changes in 
spreading ability, especially regarding filopodia formation can be assessed. 
RhoF-/- platelets were allowed to adhere to vWF immobilized on glass cover slips 
upon incubation with botrocetin to induce GPIb-IX-V signaling under static 
conditions. Integrilin which inhibits integrin aIIbb3 was added additionally to 
prevent integrin activation. Three different time points were studied. In contrast 
to fibrinogen-mediated spreading, only three spreading stages were defined. 
Phase 1 comprised quiescent discoid platelets, phase 2 platelets forming 1-3 
filopodia and phase 3 platelets with more than 3 filopodia. RhoF-/- platelets 
demonstrated unaltered filopodia formation compared to the wt at all studied time 
points. Thus, RhoF loss can be compensated effectively during platelet spreading 
(Fig. 40). 
 
 76 
 
 
Fig. 40. Adhesion and filopodia formation of platelets on immobilized vWF is unaffected 
by knockout of RhoF. (A) RhoF-/- and wt platelets spread similarly on vWF at 10 min, 20 min and 
30 minutes. In vWF-mediated adhesion, only 3 phases of spreading are discriminated. 
Representative images of wt and RhoF-/- platelets. Scale bar: 5 µm. (B) Results are displayed as 
stacked bars representing the mean percentage of platelets in each spreading phase. No 
significant difference in phase abundancy in RhoF-/- and wt platelets can be detected. 
Representative experiment with n=3 mice per group. 
 
In summary, platelet spreading of RhoF-/- platelets on fibrinogen was not impaired 
and filopodia formation upon adhesion on VWF proceeded with no apparent 
defect. As mentioned earlier, Cdc42 has been described as another member of 
the Rho family significantly contributing to filopodia formation72. However, studies 
from our group performed after the completion of this thesis showed that filopodia 
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formation was unaffected in RhoF/Cdc42 double-deficient platelets (unpublished 
results). Thus, other protein(s) seem to be required to facilitate filopodia formation 
in platelets. 
 
4. Discussion 
4.1 RhoA is a crucial regulator of MK localization and platelet 
biogenesis  
The small GTPase RhoA plays an important role in actin cytoskeleton-driven 
remodeling processes in platelets including shape change, spreading and clot 
retraction18,79,87. This study focused on the role of RhoA in megakaryopoiesis and 
MK localization. Strikingly, a significant proportion of RhoA-/- MKs was found 
inside BM sinusoids, ascribing a crucial role to RhoA in the transendothelial 
migration process. It is known that MKs extend proplatelets through gaps in the 
endothelial lining of BM sinusoids which accounts for the biggest proportion of 
produced platelets3. Additionally, whole MKs themselves can migrate into the 
intraluminal compartment through endothelial cells4, but the cellular machinery 
and the physiological conditions under which this might preferentially occur have 
not been clarified. Fostering this observation, MKs can be found in the capillary 
bed of the lung which has been shown to be the result of migration, not of edaphic 
development243,244,245,246. 
Interestingly, proplatelet formation was shown to be regulated by RhoA through 
nonmuscular myosin II (NMII) activity. Myosin II consists of 2 heavy and 4 light 
chains and is the gene product of the MYH9 gene. Inhibition of MLC 
phosphorylation or absence of MYH9 increases proplatelet formation from 
MKs19,247. RhoA typically enhances MLC phosphorylation through ROCK which 
diminishes proplatelet formation in vitro51, indicating that RhoA is a negative 
regulator of proplatelet formation. Therefore, the observed 
macrothrombocytopenia seems to be linked to the localization defect, rather than 
to deficiencies in proplatelet formation. 
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Recently, an additional model of platelet production through MK rupture was 
proposed under conditions of stress, such as acute thrombocytopenia or 
inflammation248. This research stems from the observation that MK maturation 
and platelet production can occur independently from TPO249. Moreover, in 
settings of acute hematopoietic/ megakaryocytic stress, e.g. irradiation or acute 
thrombocytopenia, HSCs were able to give rise to MKs and platelets directly 
without intermediaries248,250,251,252. The finding presented in this thesis that RhoA 
is crucial for MK localization at steady state indicated that it might also be an 
important regulator of megakaryopoiesis under stress conditions. However, the 
number of MKs at both early (1 day) and late (10 days) after experimentally 
induced thrombocytopenia was similar in BM of RhoA-/- and wt mice, not fostering 
the role of RhoA in this setting. At the same time, studies of time points in between 
day 1 and 10 seem warranted, as the platelet trough is most pronounced through 
the first few days and changes in MK numbers might occur only then, also with 
regard to the rupture model. 
It is also relevant to discuss limitations of this part of the study. Conventional 
histological analysis of the compartmentalization of MKs in the BM using 
hematoxylin eosin stained sections can make the identification of knock-out MKs 
difficult, as they may be morphologically altered as for example Cdc42-/- MKs 
exhibit reduced invaginations and demarcation from the surrounding BM stromal 
cells 149. Or they might undergo transmigration through the endothelial lining 
which could result in aberrant morphology as well. This might explain why in this 
work no increase of total MK numbers in the BM of RhoA-/- mice was observed, 
in contrast to published results18. RhoA/Cdc42-/- MKs exhibited higher numbers 
of MKs in the BM (see section 3.1.3), similar to findings from the Cdc42 single 
knock-out149. Additionally, MK numbers in the spleen were increased threefold, 
likely indicating severe stress and/ or inefficient megakaryopoiesis. Gross 
phenotypical assessment of BM structure and MKs themselves yielded 
comparable findings in RhoA/Cdc42-/- and wt MKs, but potentially left many 
structurally altered MKs unidentified. Due to this fact, MK counts in the 
RhoA/Cdc42-/- mice might be underreported by methods used in this work. 
Indeed, after the completion of this thesis, analysis of immunofluorescently 
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stained cryo sections of whole femura enabled Sebastian Dütting and other 
members of the group253 to show that RhoA/Cdc42-/- MKs were almost completely 
clustered around BM sinusoids, while being unable to transmigrate into the vessel 
lumen. Dütting et al.253 could demonstrate a regulatory circuit where RhoA 
functions as a stop-signal regarding MK transmigration while GPIb/Cdc42 
signaling forms a go-signal. The observed macrothrombocytopenia is thus in part 
a direct result of the altered MK distribution and subsequently defective platelet 
biogenesis in vivo. 
 
In this thesis, several potential signaling pathways regulating RhoA in MKs were 
investigated with the G-proteins G12 and G13 being obvious candidates, as they 
have been shown to be situated upstream of RhoA signaling in platelets154. While 
G12/13-/- mice do not exhibit macrothrombocytopenia, redundant functions of the 
proteins in MK localization cannot not be excluded. However, the MK distribution 
was similar in G12/13-/- mice compared to the wt, making a major contribution to 
RhoA signaling in MKs via these G proteins unlikely. 
Integrin aIIbb3 is the most abundant platelet surface receptor, essential in platelet 
outside-in signaling, mediating stable adhesion and being crucial for platelet 
aggregation via binding of vWF and fibrinogen. Surprisingly, integrin aIIbb3 does 
not seem to be involved in the regulation of MK localization in the BM since its 
blockade in RhoA-/- mice could not revert the MK mislocalization observed in non-
injected RhoA-/- mice. Whether other integrins, such as integrin b1 are involved 
in the regulation of MK localization, remains elusive. 
The platelet collagen receptor GPVI is a type I transmembrane protein of the Ig 
superfamily and transduces signals through its transmembrane region which 
interacts with the Fc receptor (FcR) g-chain235. Inhibitory signaling via GPVI was 
recently proposed to be involved the spatial regulation of proplatelet formation in 
vivo254. However, transiently GPVI-deficient RhoA-/- mice (treated by JAQ1 
antibody) exhibited a similar MK mislocalization in the BM as observed in non-
injected RhoA-/- mice.  
Similar to findings from JAQ1 treated RhoA-/- mice, the MK mislocalization in 
RhoA-/- mice could not be reverted by transient knock-out of Clec-2 by injection 
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of the INU1 antibody. Notably, INU1-treated RhoA-/- mice exhibited a statistically 
significant higher number of BM MKs than non-injected RhoA-/- mice. This effect 
could be due to the transient thrombocytopenia upon INU1 antibody injection182 
and the subsequent stimulation of megakaryopoiesis.  
Taken together, the selective inhibition of (hem)-ITAM signaling pathways does 
not influence RhoA signaling in terms of MK migration and compartmentalization 
in the BM. While these findings are consistent with normal platelet counts and 
thus most probably normal thrombopoiesis in GPVI- or Clec-2 knock-out mice, 
they do not exclude a redundant function of the pathways in the process of 
platelet production. 
Finally, also antibody (89F12)-mediated GPV-blockade in RhoA-/- mice was not 
able to revert the MK mislocalization observed in untreated mice. Thus, despite 
association of GPV with GPIb, GPV does not seem to be directly involved in the 
regulation of MK localization in the BM. This stands in contrast to in vivo blockade 
of GPIba by treatment of mice with p0p/B Fab fragments, which after the 
completion of this thesis was shown to revert intrasinusoidal localization of  RhoA-
/- MKs. Nonetheless, the results presented in this part of the thesis were 
confirmed later by using immunofluorescently stained cryo sections253, 
suggesting downstream signaling of the GPIb subunit of the GPIb-IX-V complex 
occurs irrespective of the functional state of GPV. 
Limitations of all the conducted antibody blockade experiments include that i.v. 
injection regimen guarantees high availability of the antibody in the circulation 
and for intraluminal MKs, but tissue penetration capabilities are not easy to 
determine and may depend on the respective antibody. 
 
4.2 RhoF is redundant in filopodia formation 
A second part of this thesis focused on the investigation of RhoF, as Cdc42-/- 
mice were macrothrombocytopenic, while demonstrating regular filopodia 
formation149. With RhoF being hypothesized to be an important (independent) 
driver of filopodia formation101, also associated changes of megakaryopoiesis 
were imaginable. In contrast to this speculation, platelet indices and platelet size 
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were comparable in RhoF-/- and wt mice indicating that there is no major defect 
in megakaryopoiesis upon RhoF deletion. Additionally, activation and 
degranulation assays showed no overt phenotype for RhoF-deficient mice. Lastly, 
upon adherence to ECM proteins, i.e. vWF and fibrinogen RhoF-deficient 
platelets adhered and spread similar as compared to the wt. Together with the 
published work by Goggs et al.161, these findings indicate a redundant role for 
RhoF in platelet biogenesis and function. 
 
4.3 Concluding remarks and outlook 
This work was targeted at studying the effects of various small GTPase single 
and double knock-outs on megakaryopoiesis, MK migration and subsequent 
compartmentalization in the BM. The observation that RhoA deficiency alters MK 
localization might be of relevance for other cell types, too which depend on 
locomotion in response to stimuli to fulfill their functions, e.g. immune cells. 
As Dütting et al.253 showed, the regulation of MK localization and transendothelial 
platelet biogenesis involves a Cdc42/RhoA regulatory circuit downstream of GPIb. 
Following up on this work, further detailed studies of potential up- and 
downstream regulators of the two GTPases in MKs will be required to decipher 
the signaling mechanism regulating platelet biogenesis in vivo. 
In the future, a three dimensional (3D) matrix in vitro model of MK maturation and 
migration in the BM niche could be helpful, too, next to in vivo experiments, to 
monitor the localization/migration of MKs in response to various stimuli and help 
clarify which further small GTPases are involved in the process and what their 
spatiotemporal regulation might be. Notably, a recent study from David Stegner 
and colleagues using 3D in vivo imaging revealed that a distinction between an 
osteal and vascular niche is not conceivable in vivo. Their results show that MK 
progenitors and mature MKs are always in close contact with the BM sinusoids 
34 leading to the revised model that thrombopoiesis is spatially regulated by the 
BM vasculature. 
 
Regarding studies on RhoF in platelets and MKs, it could prove useful to create 
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a double knock-out of Cdc42 and RhoF in mice to investigate potential redundant 
functions of the two GTPases in thrombopoiesis and filopodia formation. 
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5. Summary 
Platelets constitute the cellular component in hemostasis and play a crucial role 
in the physiological response to injuries the vessel wall to limit potential blood 
loss, but at the same time in pathological processes like plaque rupture due to 
atherosclerosis, where their activation and aggregation facilitates arterial 
thrombosis leading to ischemic stroke or myocardial infarction. 
This work focuses on megakaryocyte physiology with a special interest in the 
description of the localization of MKs in the bone marrow in mice single-deficient 
of the small Rho GTPase RhoA or double-deficient for RhoA and Cdc42 – another 
important Rho GTPase in transgenic mice. The importance of Rho GTPases in 
platelet and megakaryocyte physiology has already been extensively 
investigated with RhoA being responsible for creation of focal adhesions and 
actomyosin contractions in platelets, whereas Cdc42 has been shown to be 
important for microtubule rearrangements in megakaryocytes in conjunction with 
Rac1. RhoA ko mice were generated and studied with regard to 
compartmentalization of megakaryocytes in the bone marrow, revealing the 
intraluminal presence of megakaryocytes in bone marrow sinusoids. In a next 
step, aggravation, confirmation or abolishment of this finding was studied in 
related mouse strains, namely a RhoA/Cdc42 and G12/G13 (upstream regulators 
of RhoA activity) dko. Finally, RhoA ko mice treated with antibodies that block 
different specific surface receptors were studied in regard to MK 
compartmentalization. 
In the second and smaller part of this thesis the role of RhoF, a Rho GTPase 
which has been postulated to be of importance in filopodia formation in addition 
to Cdc42, in platelet function was investigated by analyzing a RhoF ko mouse 
strain. Receptor expression, platelet activation, granule release and filopodia 
formation in response to various stimuli in RhoF-deficient platelets was studied, 
showing no significant difference compared to the wild-type. 
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Zusammenfassung 
Blutplättchen stellen die zelluläre Komponente der Blutgerinnung und spielen 
eine entscheidende Rolle in der physiologischen Antwort auf Verletzungen der 
Gefäßwand, um etwaigen Blutverlust zu vermindern, aber gleichzeitig auch in 
pathologischen Prozessen wie durch Atherosklerose vermittelter Plaqueruptur 
bei denen ihre Aktivierung und Aggregation zu ischämischem Schlaganfall oder 
Myokardinfarkt führen kann. 
Diese Arbeit beschäftigt sich mit Megakaryozyten, den Vorläuferzellen der 
Thrombozyten, mit besonderem Fokus auf der Beschreibung ihrer Verteilung im 
Knochenmark in Abhängigkeit von der Defizienz der kleinen Rho GTPase RhoA 
und der kombinierten Defizienz von RhoA und Cdc42 – einer anderen 
bedeutenden Rho GTPase in transgenen Mauslinien. Die Bedeutung der Rho 
GTPasen in der Megakaryopoiese und Thrombozytenphysiologie wurde bereits 
ausgiebig untersucht. So ist RhoA verantwortlich für die Schaffung fokaler 
Adhäsionen und die Kontraktilität des Aktin-Myosinapparates, wohingegen für 
Cdc42 zusammen mit Rac1 eine Bedeutung im Mikrotubuli Re-Arrangement in 
Megakaryozyten gezeigt werden konnte. RhoA defiziente Mäuse wurden 
generiert und die megakaryozytäre Kompartimentalisierung innerhalb des 
Knochenmarkssinusoide analysiert mit dem erfolgreichen Nachweis intraluminal 
gelegener Megakaryozyten. In einem nächsten Schritt wurden eine RhoA/Cdc42 
doppeldefiziente und eine Mauslinie mit Doppeldefizienz in G12/G13 (in der 
Signalkaskade oberhalb gelegene Regulatoren der RhoA Aktivität) auf eine 
Verstärkung, Bestätigung oder einen Verlust intraluminal gelegener 
Megakaryozyten untersucht. Letztlich wurden RhoA defiziente Mäuse mit 
verschiedenen, bestimmte Oberflächenrezeptorproteine blockierenden 
Antikörpern behandelt und der Einfluss auf die megakaryozytäre 
Kompartimentalisierung untersucht. 
Ein zweiter, kleinerer Teil dieser Arbeit beschäftigte sich mit der Funktion von 
RhoF, einer kleinen Rho GTPase, von der angenommen wird neben Cdc42 für 
die Filopodienausbildung verantwortlich zu sein. Hierzu wurde eine RhoF-
defiziente Mauslinie analysiert. Die Oberflächenrezeptorexpression, Aktivierung, 
Granulafreisetzung und Filopodienausbildung RhoF defizienter Blutplättchen in 
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Abhängigkeit verschiedener Stimuli wurde entsprechend untersucht, allerdings 
ohne Nachweis signifikanter Unterschiede zum Wildtyp. 
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7. Appendix 
7.1 Abbreviations 
 
3D three dimensional 
ADP adenosine nucleotide diphosphate 
AMR Ashwell-Morrell receptor 
Arp actin related protein 
ATP adenosine nucleotide triphosphate 
BD Becton Dickinson 
BSA bovine serum albumin 
C Celsius 
c-Src cellular Sarcoma kinase 
CalDAG-GEF1 Ca2+ and diacylglycerol-regulated 
guanine nucleotide exchange factor 1 
cAMP cyclic adenosine monophosphate 
CAMT congenital amegakaryocytic 
thrombocytopenia 
Cdc42 cell division cycle protein 42 
cGMP cyclic guanosine monophosphate 
CIP4 cdc42-interacting protein 4 
CRP collagen-related peptide 
CVX convulxin 
DAG diacylglycerol 
ddH2O double-distilled water 
DIC differential interference contrast 
dko double knock-out 
DMS demarcation membrane system 
DNA deoxyribonucleic acid 
DOCK dedicator of cytokinesis protein 
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e.g. example given 
EB3 end-binding protein 3 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
et al. et alteri 
EtOH ethanol 
FACS Fluorescence activated cell sorting 
FcR Fc receptor 
fg fibrinogen 
FGF-4 fibroblast growth factor-4 
fig figure 
fl flox 
FLC fetal liver cells 
FLI1 Friend leukemia virus integration 1 
FOG Friend of GATA 
G6b-B G6b-B receptor of the Immunoglobulin 
superfamily   
GAP GTPase-activating protein 
GATA GATA transcription factor 
GDI guanine nucleotide-dissociation 
inhibitor 
GDP guanine nucleotide diphosphate 
GEF guanine nucleotide triphosphate 
exchange factor 
GP glycoprotein 
GPCR G-protein coupled receptor 
GPCR G-Protein coupled receptor 
GTP guanine nucleotide triphosphate 
GTPase guanine nucleotide triphosphate 
hydrolase 
H2O2 hydrogen peroxide 
 107 
HE hematoxylin and eosin 
HRP horse radish peroxidase 
HSC hematopoietic stem cell 
i.e. id est, that is 
i.p. intraperitoneally 
i.v. intravenously 
IHC immunohistochemistry 
IL interleukin 
IL interleukin 
IP3 inositol 1,4,5-triphosphate 
IQGAP1/2 IQ-domain containing GAP 1/2 
IRSp53 insulin-receptor substrate p53 
ITIM immunoreceptor tyrosine-based 
inhibition motif 
IVS invaginated membrane system 
JAK Janus kinase 
KLF1 Kruppel-like factor 1 
ko knock-out 
LIMK LIM kinase 
mab monoclonal antibody 
MAPK mitogen activated protein kinase 
mDia mammalian diaphanous 
ME-P megakaryocyte/erythroid-progenitor 
min minute 
MK megakaryocyte 
MK-P megakaryocyte-progenitor 
MMP matrix metalloprotease 
Mpl Myeloproliferative Leukemia Protein 
MVS multivesicular bodies 
MYH myosin heavy chain 
N-WASP neuronal-Wiskott-Aldrich syndrome 
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protein 
nonmuscle myosin NM 
OPHN1 oligophrenin 
P-Rex phosphatidylinositol 3,4,5-
trisphosphate-dependent Rac 
exchanger 
PAK p21-activated kinase 
PAR protease-activated receptor 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PECAM-1 Platelet Endothelial Cell Adhesion 
Molecule-1 
PF-4 platelet factor-4 
PFA paraformaldehyde 
PGE1 prostaglandin E1 
PGI2 prostacyclin 
PI3K phosphatidyl inositol 3 kinase 
PKC protein kinase C 
plt platelet 
prp platelet rich plasma 
Rac1 Ras-related C3 botulinum toxin 
substrate 1 
Ras rat sarcoma 
RC rhodocytin 
RhoA Ras homologue A 
RIAM Rap1-interacting adaptor molecule 
ROCK Rho-associated protein kinase 
rpm rounds per minute 
RT room temperature 
Runx runt-related transcription factor 
S1P sphingosine 1-phosphate 
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Scar suppressor of cyclic AMP receptor 
SCF stem cell factor 
SDF-1 stromal cell-derived factor 1 
sec second 
SFK Src family kinase 
Shp SH2 domain-containing protein 
phosphatase 
STAT Signal Transducer and Activator of 
Transcription 
TBS Tris buffered saline 
TEM transmission electron microscopy 
TIAM T-cell Lymphoma Invasion and 
Metastasis protein 
TP thromboxane-prostanoid 
TPO thrombopoietin 
TRAP thrombin receptor-activating peptide 
TxA2 thromboxane A2 
U-46 U-46619 
VASP vasodilator-stimulated 
phosphoprotein 
Vav onc F proto-oncogene 
VCAM vascular cell adhesion molecule 
VEGFR vascular endothelial growth factor 
receptor 
VLA very late antigen 
vol volume 
vWF von Willebrand Factor 
WASP Wiskott-Aldrich syndrome protein 
WAVE WASP-family Verprolin homologous 
wt wild-type 
b-PIX Rho guanine nucleotide exchange 
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factor (GEF) 7b 
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